

Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion

Guilherme Pedreira de Freitas Nader, Sonia Agüera-Gonzalez, Fiona Routet, Matthieu Gratia, Mathieu Maurin, Valeria Cancila, Clotilde Cadart, Andrea Palamidessi, Rodrigo Nalio Ramos, Mabel San, et al.

► To cite this version:

Guilherme Pedreira de Freitas Nader, Sonia Agüera-Gonzalez, Fiona Routet, Matthieu Gratia, Mathieu Maurin, et al.. Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion. Cell, 2021, 10.1016/j.cell.2021.08.035 . hal-03392287

HAL Id: hal-03392287 https://hal.science/hal-03392287v1

Submitted on 21 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Title: Compromised nuclear envelope integrity drives TREX1-dependent 2 DNA damage and tumor cell invasion

3

4 Authors: Guilherme Pedreira de Freitas Nader¹, Sonia Agüera-Gonzalez², Fiona Routet²,

5 Matthieu Gratia³, Mathieu Maurin³, Valeria Cancila⁴, Clotilde Cadart^{1,5}, Andrea Palamidessi¹¹,

- 6 Rodrigo Nalio Ramos¹², Mabel San Roman³, Matteo Gentili^{3,6}, Ayako Yamada^{7,8}, Alice Williart¹,
- 7 Catalina Lodillinsky^{9,10}, Emilie Lagoutte², Catherine Villard⁷, Jean-Louis Viovy⁷, Claudio
- 8 Tripodo⁴, Jérôme Galon¹², Giorgio Scita¹¹, Nicolas Manel^{3§}, Philippe Chavrier^{2§}, Matthieu
- 9 Piel^{1§&}

10 Affiliations:

- 1 Institut Curie and Institut Pierre Gilles de Gennes, PSL Research University, CNRS, UMR
 144, Paris, France
- 13 2 Institut Curie, PSL Research University, CNRS, UMR 144, Paris, France
- 14 3 Institut Curie, PSL Research University, INSERM, U 932, Paris, France.
- 15 4 Tumor Immunology Unit, University of Palermo, Corso Tukory 211, 90234, Palermo, Italy
- 16 5 Current address: Molecular and Cell Biology Department, University of California, Berkeley,
- 17 142 Life Sciences Addition #3200, Berkeley, CA 94720-3200, USA
- 6 Current address: Broad Institute of MIT and Harvard, 415 Main Street, Cambridge, MA
 02142, USA
- 20 7 Institut Curie, Université PSL, CNRS, UMR 168, Paris, France
- 8 Current address: PASTEUR, Département de chimie, École normale supérieure, Université
 PSL, Sorbonne Université, CNRS, Paris, France
- 9 Research Area, Instituto de Oncología Ángel H. Roffo, Universidad de Buenos Aires, Buenos
 Aires, Argentina
- 10 Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires,
 Argentina
- 11 IFOM, the FIRC Institute of Molecular Oncology IFOM. Via Adamello 16 20139 Milano &
 Department of Oncology and Hemato-oncology, University of Milan. IFOM. Via Adamello 16
 20139 Milano, Italy
- 12 INSERM, Sorbonne Université, Université de Paris, Equipe Labellisée Ligue Contre le Cancer, Centre de Recherche des Cordeliers, Laboratory of Integrative Cancer Immunology,
- 32 Paris, France.
- 33
- 34 § These authors contributed equally to the supervision of the work
- 35 & Lead contact: <u>matthieu.piel@curie.fr</u>
- 36 Correspondence should be sent to: <u>nicolas.manel@curie.fr</u>, <u>philippe.chavrier@curie.fr</u>,
 37 <u>matthieu.piel@curie.fr</u>
- 38

1 Summary

While mutations leading to a compromised nuclear envelope cause diseases such as muscular 2 dystrophies or accelerated aging, the consequences of mechanically induced nuclear 3 envelope ruptures are less known. Here we show that nuclear envelope ruptures induce DNA 4 5 damage which promotes senescence in non-transformed cells, and induces an invasive phenotype in human breast cancer cells. We find that the ER-associated exonuclease TREX1 6 translocates into the nucleus after nuclear envelope rupture and is required to induce DNA 7 damage. Inside the mammary duct, cellular crowding leads to nuclear envelope ruptures which 8 9 generate TREX1-dependent DNA damage, thereby driving the progression of *in situ* carcinoma to the invasive stage. DNA damage and nuclear envelope rupture markers were also enriched 10 at the invasive edge of human tumors. We propose that DNA damage in mechanically 11 12 challenged nuclei could affect the pathophysiology of crowded tissues by modulating proliferation and extracellular matrix degradation of normal and transformed cells. 13

14 Introduction

In tissues, extracellular matrix fibers and cell packing limit the available space. Migrating and 15 proliferating cells thus often face situations of crowding and confinement, which can result in 16 strong cell and nucleus deformations. We and others showed that, in the case of migrating 17 18 immune and cancer cells, strong nuclear deformation can result in transient events of nuclear envelope (NE) rupture with subsequent DNA damage (Denais et al., 2016; Hatch, 2018; Hatch 19 20 and Hetzer, 2016; Irianto et al., 2017; Raab et al., 2016). In this context, efficient repair 21 responses are essential to ensure cell viability, which involve ESCRT proteins restoring NE 22 integrity, as well as BAF1 and the DNA repair pathways (Lusk and Ader, 2020). NE ruptures can be induced by simply confining cells between two plates, independently of their migratory 23 24 behavior (Le Berre et al., 2012; Gentili et al., 2019; Hatch and Hetzer, 2016). They can also occur spontaneously in fragile mutant nuclei (Vargas et al., 2012; De vos et al., 2011), 25 26 associated with a large range of degenerative diseases (Robijns et al., 2018). Recent studies 27 showed that these events also occur in vivo such as in muscle tissues which are highly solicited mechanically; in the heart of developing embryos, due to stiffening and beating of the tissue 28 29 (Cho et al., 2019), as well as in skeletal muscle cells harboring mutations in the lamin A/C gene, due to forces exerted on the nuclei by the microtubule cytoskeleton (Earle et al., 2020; 30 Roman et al., 2017). In these tissues, NE ruptures are associated with senescence and aging 31 phenomena that affect cell proliferation, survival, and ultimately tissue function. NE ruptures 32 33 are often accompanied by DNA damage (Cho et al., 2019; Denais et al., 2016; Earle et al., 2020; Feng et al., 2018; Raab et al., 2016). Mechanisms leading to senescence and DNA 34 damage upon NE rupture are unclear. Here, we investigated the consequences of nuclear 35 deformation and rupture associated with cell migration in crowded tissues, focusing on 36 37 mammary carcinoma. These tumors, which grow confined inside the mammary ducts, have been shown to display large strands of collectively moving cells associated with the transition 38 39 from in situ to the invasive stage of the tumor development (Palamidessi et al., 2019). 40 Additionally, the breast neoplastic invasive switch requires the activity of matrix proteases for 41 breaching out of the duct (Feinberg et al., 2018; Lodillinsky et al., 2016).

42 Results

We first investigated human samples of breast ductal adenocarcinoma in situ with 43 microinvasion stained by immunohistochemistry for the small GTPase RAB5A (involved in 44 recycling of cell/cell adhesions, used as a marker for strands of motile cells (Malinverno et al., 45 2017) and the DNA damage marker phospho-yH2AX. We observed that tumor regions positive 46 for RAB5A, often corresponding to micro-invasive foci (see methods and (Kim et al., 2018)). 47 displayed a larger number of deformed and elongated nuclei (Fig. 1A-E). This morphology 48 corresponds to cells squeezing each other as they move (Friedl and Gilmour, 2009; 49 Palamidessi et al., 2019). Nuclei positive for yH2AX were more abundant in invasive foci than 50 in the tumor bulk (Fig. 1D), and, within invasive foci, vH2AX-positive nuclei were more often 51 found in cells with higher RAB5A expression (presumably more migratory (Palamidessi et al., 52

2019), Fig. 1E). This suggests that strands of motile cells at the periphery of the tumor exhibit
 pronounced nuclear deformation, associated with elevated DNA damage.

3 We then investigated a xenograft mouse model based on the intraductal (intra-nipple) injection 4 of transformed human breast cancer MCF10DCIS.com (DCIS hereafter) cells, which are 5 derived from the non-tumorigenic breast epithelial MCF10A cell line. This model recapitulates the transition from *in situ* to invasive stages of breast cancer progression (Behbod et al., 2009; 6 7 Lodillinsky et al., 2016). In situ tumors are characterized by a myoepithelial layer (stained with smooth muscle actin) surrounding human xenografted cells (identified by a human-specific 8 KU70 antibody, Fig. 1F). Tumor sections were stained with vH2AX (Fig. 1F-G). Advanced 9 tumors (classified based on the state of the myoepithelial layer) displayed more yH2AX-10 positive nuclei (Fig. 1F). Deformed nuclei were mostly found at the periphery of the tumor 11 mass, especially in ducts inflated with large tumors, and enriched in micro-invasive foci (Fig. 12 1G). Most of the vH2AX-positive nuclei did not correspond to mitotic nor apoptotic figures (Fig. 13 S1A), which were excluded from the analysis. We performed an automated analysis of all 14 human nuclei in the tumor regarding their level of yH2AX staining, as a function of their 15 distance to the tumor edge (Fig. S1A for the method). This analysis showed an enrichment for 16 nuclei with an elevated yH2AX staining (Z-score above 2) and even more for nuclei with a very 17 18 high staining (Z-score above 5) in the region closer to the tumor edge (Fig. S1B and Fig. 1H). 19 Together, these data show that the periphery of mammary in situ carcinomatous lesions, both in human and in xenografted mice, often display strongly deformed nuclei with elevated levels 20 of DNA damage. This raises the possibility that NE ruptures could be implicated in the induction 21 22 of the DNA damage, as suggested by previous work on migrating cells (Denais et al., 2016; 23 Raab et al., 2016).

24 Because NE ruptures of deformed nuclei were difficult to investigate in tumor samples, we developed a 'duct-on-chip' microfluidic assay (inspired by (Blaha et al., 2017)). The assay 25 consists of three large 50 µm-high channels: a lateral channel filled with culture medium, a 26 central one with DCIS cells, and the third channel with a dense fluorescently-labeled type I 27 28 collagen fibrillar matrix. The channels are connected by regularly spaced V-shape gates, 10 29 µm-wide in their smaller section, through which cells can migrate towards the collagen-filled chamber (Fig. 1I and Fig. S1C). Cells invaded efficiently the collagen chamber (Fig. 1I) and 30 visualization of the collagen network suggested that they were able to remodel the collagen 31 32 fibers over time (Fig. 1I). Using a pan inhibitor of matrix metalloproteinases (MMPs), GM6001, we confirmed that collagen degradation by DCIS cells was required for invasion into the 33 collagen chamber (Fig. S1D, E), similar to what we had previously observed in vivo (Lodillinsky 34 35 et al., 2016). DCIS cells expressing catalytically inactive cGAS-mCherry (icGAS hereafter) to 36 detect NE ruptures (Gentili et al., 2019; Raab et al., 2016), and 53BP1-GFP to detect DNA 37 double-strand break (DSB) foci were grown in the device. The average cell density increased by 50% from 24h to 48h after cell loading (Fig 1I). The device was loaded either with a low or 38 39 a high density of cells (Fig. S1 F, G, H), so that, after 48 hours, the low-seeding density would remain below the initial high-seeding density. We then quantified the shape of nuclei, the 40 number of 53BP1-GFP foci and the fraction of nuclei showing icGAS-mCherry peripheral 41 accumulation, characteristic of NE rupture events (Fig. S1H, (Raab et al., 2016)). 48 h after 42 seeding at high, but not at low density, nuclear roundness decreased, indicating that nuclei 43 44 were getting confined and deformed (Fig. 1J), and the fraction of nuclei with NE ruptures and 45 elevated 53BP1 foci (> 3) increased (Fig. 1 K, L). DCIS cells remained motile even at high density (Movie S1, (Malinverno et al., 2017; Palamidessi et al., 2019)). This suggests that, 46 similarly to what was observed for single migrating cells in a dense tissue (Denais et al., 2016; 47 48 Raab et al., 2016), the motility of DCIS cells in a crowded multicellular context can lead to nuclear deformation, NE rupture and DNA damage. 49

50 To examine the link between nuclear deformation, NE rupture and DNA damage, we used a 51 2D confiner device that allows precise deformation of cells (and nuclei) between two parallel 52 plates (Le Berre et al., 2014). In addition to DCIS cells, we analyzed the non-tumorigenic cell 53 lines RPE1 (normal human hTERT immortalized cells, in which we have previously

characterized NE ruptures and DNA damage in migration assays (Raab et al., 2016) and 1 2 MCF10A expressing icGAS-mCherry and 53BP1-GFP (Fig. 2A). We found a sharp increase in the fraction of RPE1 cells with ruptured nuclei below 3 µm confinement (Fig. S2A, B), 3 confirming our previous observations on another panel of cell types (Raab et al., 2016). To 4 5 assess the relationship between NE rupture and DNA damage, we analyzed the number of 6 53BP1-GFP foci in nuclei of cells confined at various heights and displaying NE ruptures or not (Fig. S2A). Foci were counted at each time-point using a semi-automated process (see 7 8 methods and Fig. S2C). We found that, similarly to cells migrating through constrictions (Raab et al., 2016), only cells with ruptured NE displayed increased number of 53BP1 foci (Fig. 2B-9 D for RPE1 and S2D for DCIS and MCF10A). Almost all cells with NE rupture (> 98%) 10 displayed more than three 53BP1 foci (Fig. 2E-F), while only a small fraction of cells without 11 NE rupture (< 2%) had this number of foci over the course of the movie (Fig. 2E). Analysis of 12 13 the intensity of foci and of the background (Fig. S2E) showed that 53BP1 accumulated in an 14 increasing number of foci in nuclei with NE ruptures. Cells exhibiting NE ruptures were also positive for other markers of DNA damage, such as RIF1 and yH2AX (Fig S2F, G). Additionally, 15 16 the number of 53BP1 foci per nucleus did not depend on the cell cycle (Fig. S2H). Collectively, these results indicate that confinement-induced DNA damage was preceded by NE rupture 17 events in a variety of cells, including RPE1 (in accordance with other reports (Raab et al., 2016; 18 Shah et al., 2021)), MCF10A and DCIS cells. 19

In cells displaying NE ruptures, the number of 53BP1 foci remained high throughout the confinement period (Fig. 2C and S2D), and was associated with a majority of cells showing repeated cycles of NE blebbing, rupture and repair over the entire duration of confinement, in contrast to cells confined at 4 μ m (Movie S2). We thus hypothesize that the occurrence of DNA damage associated with deformed nuclei in the human tumor samples could correspond to repeated NE ruptures.

26 Previous work suggested that NE rupture might lead to DNA repair proteins leaking out the 27 nucleus (Irianto et al., 2017). Some cytoplasmic factor(s) might also enter the nucleus and access nuclear DNA, causing DNA damage (Maciejowski et al., 2015, 2019; Shah et al., 2017). 28 Live recording of 53BP1-GFP showed the expected dynamic appearance and disappearance 29 30 of single foci, indicative of DNA damage and repair events (Fig. 2G and Movie S2). We found that the frequency of appearance of new foci was significantly higher in cells with NE rupture 31 with respect to cells without NE rupture, reaching almost the same rate as upon etoposide 32 33 treatment (Fig. 2H). Moreover, the number of new foci typically increased after a rupture event (Fig. S2I, J), suggesting a causal relationship between NE rupture and new DNA damage. On 34 the contrary, lifetime of the foci showed no difference between cells with or without NE ruptures 35 (Fig. 2I). Overall, these experiments suggest that DNA damage associated with NE ruptures 36 is mostly due to the generation of new DNA damage following NE rupture events rather than 37 38 to delayed repair.

To investigate whether DNA damage was solely associated to NE rupture events or whether 39 cell and nuclear confinement were also required, we recorded non-confined cells plated on a 40 glass coverslip. In these conditions, although very rare, spontaneous NE rupture events could 41 be observed. Such events displayed a similar signature in terms of icGAS accumulation at a 42 43 local site on the nuclear periphery and leakage of 53BP1-GFP staining in the cytoplasm before re-import into the nucleus (Fig. 2J and Movie S3). Each NE rupture event was followed, within 44 1 to 2 hours, by an increase in the number of 53BP1-GFP foci in the nucleus (Fig. 2J-L). To 45 46 investigate a larger population of cells, we fixed the cells and counted the number of foci using 53BP1-GFP (Fig. 2M, left), or γ H2AX staining (Fig. 2M, right), in cells with or without NE rupture 47 48 (assessed by the presence of an icGAS perinuclear accumulation). The increase in the number 49 of foci appeared similar to the one observed after confinement-induced NE ruptures. Together these experiments indicate that DNA damage follows NE rupture events even in the absence 50 51 of confinement.

NE ruptures at persistent post-mitotic exit chromatin bridges have been shown to cause DNA 1 2 damage, reduced upon depletion of TREX1, a cytoplasmic ER membrane-associated exonuclease (Maciejowski et al., 2015). We silenced TREX1 by siRNA-mediated knockdown, 3 or permanently knocked it out by CRISPR technology (in RPE1 and DCIS cells, Fig. S3A, B). 4 5 We found that, upon TREX1 depletion in the three cell lines (RPE1, MCF10A, DCIS), NE ruptures were no longer accompanied by an increase in 53BP1 foci (Fig. 3A, B, Fig. S3C-D, 6 quantified by an independent method in Fig. S3E). TREX1 depletion also prevented the 7 8 occurrence of DNA damage upon spontaneous NE rupture events in RPE1 cells (Fig. 3C, S4A, B). 53BP1 foci mean intensity (Fig. S3F), the generation of foci upon etoposide treatment (Fig. 9 S3G) and NE rupture frequency (Fig. S3H) were not affected. Wild-type TREX1, but not of a 10 catalytically-deficient mutant (TREX1-D18N, (Lehtinen et al., 2008)) increased the number of 11 foci in cells with NE ruptures (Fig. 3A, B). These experiments unambiguously demonstrate a 12 13 role for TREX1 in promoting DNA damage upon NE rupture events in this panel of cell lines.

To determine how TREX1 gains access to nuclear DNA upon NE rupture events, we imaged 14 15 TREX1-GFP expressing cells. In non-confined cells, TREX1-GFP was mostly bound to endomembranes and excluded from the nucleoplasm. Upon confinement, TREX1-GFP foci 16 were also found inside the nucleus (Fig. S3I, Movie S4). Immuno-electron microscopy using 17 18 gold immunolabelling against mCherry on RPE1 TREX1 KO cells reconstituted with TREX1mCherry, showed that, in non-confined cells, gold particles were found at ER membranes 19 distributed throughout the cytosol, co-localizing with the ER-resident enzyme, protein disulfide 20 isomerase (PDI) (Fig. 3D and S4C). PDI and TREX1 staining were increased inside the 21 nucleus in 2 µm confined cells (Fig. 3D-E and S4C). TREX1 was particularly enriched at the 22 inner nuclear membrane of confined cells (Fig. S4C, and Tables S1 and S2, (Mayhew, 2011)). 23 When localized inside the nucleus, TREX1-mCherry appeared associated to ER-like 24 25 membranes together with PDI (Fig. 3D). The presence of such intranuclear ER-like membranes was almost never observed in non-confined cells. These experiments suggest 26 27 that, upon strong confinement corresponding to heights at which cells undergo NE rupture 28 events, TREX1 localizes, together with other ER-bound proteins like PDI, from cytosolic ER, to the inner side of the nuclear membrane and the inside of the nucleus, but remains mostly 29 bound to membranes. 30

Because TREX1 is an ER membrane protein, and based on the immuno-electron microscopy 31 results, we hypothesized that TREX1 might access the chromatin by diffusion from the ER 32 33 membrane to connected intra-nuclear membranes ((Ungricht and Kutay, 2015)). Accordingly while WT TREX1 fully rescued the level of DNA damage induced by NE rupture in TREX1 KO 34 35 DCIS cells, the DeltaC construct, lacking the C-terminal ER-binding site of the protein, failed to do so (Fig. S3J, K). A construct in which the C-terminus of the protein was replaced by the 36 ER binding site of Sec61 (Mohr et al., 2021) was able to partially rescue the level of DNA 37 38 damage induced by confinement in TREX1 KO DCIS cells (Fig. S3J,K), similarly to what was observed in micro-nuclei (Mohr et al., 2021). Together, these experiments suggest that, upon 39 NE rupture events, ER bound TREX1 gains access to the interior of the nucleus, causing DNA 40 41 damage.

42 Having established a mechanism of DNA damage generation after NE rupture, we next sought 43 to examine the functional consequences of this damage. In non-transformed cells, chronic exposure to DNA damage-inducing factors is associated with cellular senescence. RPE1 and 44 MCF10A cells showed a very clear induction of senescence upon treatment with etoposide 45 46 and doxorubicin (hereafter referred to as doxo) as verified by senescence-associated-βgalactosidase (B-gal)-positive staining. However, senescence was less pronounced in the 47 tumorigenic DCIS cells (Fig. S5A). During confinement, even for long confinement periods, 48 most of the cells had not undergone mitosis nor shown any sign of death (Fig. S5B and C). 49 Following confinement, cells were harvested and replated in order to track single cells that had 50 ruptured their NE or not based on icGAS perinuclear staining/distribution (Fig S5D). After a 51 short period of confinement (2h), de-confined cells resumed proliferation with an almost normal 52 cell cycle duration (Fig. 4A, mean cell cycle duration for non-confined cells: 14.66 h +/- 2.31), 53

regardless of their NE status. In contrast, after a long period (12h), cells that displayed NE ruptures, while showing no sign of death, did not resume proliferation (Fig. 4A, right panel) whereas the few dividing cells showed a much longer cell cycle duration (Fig. 4A). These results suggest that NE rupture and sustained confinement delayed cell cycle progression.

5 To characterize the senescence phenotype associated with strong confinement, RPE1 cells were confined for short or long periods of time, under weak (4 μ m) or strong (2 μ m) 6 confinement, then harvested and replated for 96 h before testing a panel of senescence 7 markers (β -gal positivity, heterochromatin foci-HP1y staining, western blot for lamin B1 and 8 p21(Gorgoulis et al., 2019)). All these markers consistently showed that, while short term or 9 weak (4 µm) confinement did not induce senescence, long term, strong confinement, induced 10 a robust senescence phenotype, in both RPE1 and MCF10A, but not in DCIS cells (Fig 4B-G 11 and S5E-G). TREX1-depleted and TREX1 KO RPE1 cells showed no sign of senescence even 12 after strong and prolonged confinement (Fig. 4B, C, E-G and Fig. S5E) and expression of 13 TREX1 WT in TREX1 KO cells rescued the induction of p21 by confinement in RPE1 cells (Fig. 14 15 4E). The senescence phenotype was not dependent on the activation of the canonical cGAS pathway ((Gorgoulis et al., 2019)), since RPE1 cells do not express cGAS (Fig S5H (Basit et 16 al., 2020)) and did not show any sign of cGAS enzymatic activity in response to transfected 17 18 DNA (Fig. S5I). Together, these results show that TREX1-dependent chronic DNA damage induced upon strong confinement triggers the hallmarks of the senescence program in normal 19 RPE1 and MCF10A cells, but not in transformed DCIS cells. 20

To investigate the potential consequences of DNA damage associated with NE ruptures during 21 the development of tumors produced by DCIS cells, we used the duct-on-chip assay described 22 23 above. Both control- and TREX1-depleted cells reached high density within 48 h after injection in the device, showing that proliferation was not affected by TREX1 depletion. They also 24 25 displayed comparable levels of NE ruptures (Fig. 5A). After 24 h in the device, there was no appreciable difference in 53BP1 foci numbers between control- and TREX1-depleted cells 26 27 (Fig. 5A). In contrast, while this number significantly increased at 48 h for control cells, it 28 remained constant in TREX1-depleted cells (Fig. 5A). These results indicate that the increased 53BP1 foci levels observed at high density in the duct-on-chip system is a consequence of 29 TREX1-dependent DNA damage following nuclear deformations and ruptures. 30

TREX1-depleted DCIS cells can thus grow at high density in the duct-on-chip device without 31 showing an increase in DNA damage. We found that control cells invaded the collagen 32 33 chamber earlier and migrated farther than TREX1-depleted cells (Fig. 5B). This suggests that the increased invasive behavior of control cells might be due more elevated DNA damage. To 34 test this hypothesis, differently-labelled control and doxo-treated cells were mixed and 35 introduced in the duct-on-chip device. We observed that 24 h after loading the cells into the 36 device (to ensure that cell density was still low), doxo-treated cells displayed increased 37 38 invasion potential into the collagen chamber as compared to DMSO-treated cells (Fig 5C). 39 These results indicate that sustained DNA damage can be a driver of the invasive behavior of DCIS cells in a 3D matrix environment. We thus assessed the collagen degradation activity of 40 41 DCIS cells using an antibody that recognizes the collagenase-cleaved ³/₄ fragment of collagen I (Castagnino et al., 2018: Infante et al., 2018: Lodillinsky et al., 2016), Cells were first treated 42 with drugs, or confined for several hours, and then were embedded in a 3D collagen gel in the 43 absence of any further DNA damaging condition. We first treated DCIS cells with increasing 44 45 doses of doxo and observed a dose-dependent increase in collagen degradation (Fig. S6A), 46 suggesting that prior exposure to DNA damage promotes the collagen degradation capacity of 47 DCIS cells. We then assayed cells after confinement. Once in the gel, the nuclear area of the cells that had been confined at various heights, was comparable (Fig. S6B), showing no long-48 49 lasting nuclear deformation. TREX1-proficient cells that had been confined at 2 µm height, but not TREX1-depleted cells, showed a persistent, highly polarized morphology, increased speed 50 in the collagen network (Fig. S6C, guantified in D and Movie S5), and augmented collagen 51 degradation (Fig. 5D-F). In agreement, overexpressing TREX1-WT augmented collagen 52 53 degradation, while TREX1-D18N did not (Fig. 5E). Doxo treatment induced collagen

degradation in TREX1-depleted cells (Fig. S6E), confirming that TREX1 acts upstream of DNA
 damage to induce collagen degradation. Taken together, these experiments show that, upon
 strong confinement, TREX1-dependent DNA damage leads to a sustained increase in collagen
 degradation by DCIS cells.

To further clarify how TREX1-mediated DNA damage induces collagen degradation, cells 5 confined at 2 µm height were treated with the MMP inhibitor, GM6001, or with the ATM inhibitor 6 KU-55933. Both treatments inhibited collagen degradation (Fig. 5G). DNA damage during 7 interphase might lead to cGAS activation and the establishment of an EMT-like phenotype 8 (Harding et al., 2017). cGAS-depletion showed that, similarly to the senescence phenotype in 9 RPE1 cells, the induction of collagen degradation upon confinement was not cGAS-dependent 10 (Fig. S6F). Increased cellular motility and invasion induced by prolonged DNA damage and 11 ATM activation has been shown to promote a partial EMT state (Peng et al., 2019; Sun et al., 12 2012). We analyzed the mRNA expression level of a series of canonical EMT genes in cells 13 confined at 10 (control) or 2 µm, comparing WT and TREX1 KO cells. We found that SNAIL1 14 was specifically upregulated by confinement at 2 µm and that SNAIL1 mRNA induction did not 15 occur in two independent TREX1 KO clones (Fig. S6G). In the absence of confinement, 16 17 SNAIL1 was induced by both Doxo and etoposide with a peak at 4 h of treatment (Fig. S6H). Moreover, SNAIL1 silencing abrogated the increase in collagen degradation upon confinement 18 (Fig. S6I). Together, these results suggest that a partial EMT phenotype, including increased 19 20 matrix degradation and invasive potential, is induced in DCIS cells due to prolonged exposure to DNA damage. 21

22 Putting these results in the context of our initial observations of nuclear deformation and DNA damage both in human breast ductal carcinoma and intraductal DCIS cell tumor xenografts 23 24 (Fig. 1), we hypothesized that TREX1 is responsible for DNA damage in these deformed nuclei, favoring a collagen degradation program, ultimately promoting the in situ-to-invasive 25 carcinoma transition. To test directly this hypothesis in an in vivo murine model, we injected 26 either parental or TREX1 KO DCIS cells inside the mammary ducts of immuno-suppressed 27 mice and allowed tumors to develop for 6 to 8 weeks. Both parental- and TREX1 KO-injected 28 mice formed intraductal in situ tumors at a similar rate (Fig. S6J). However, there was a sharp 29 30 decrease in the tumor area of TREX1 KO-injected mice compared to parental-injected mice (Fig. S6K, L). Strikingly, while all the mice injected with parental DCIS cells showed invasive 31 tumors based on whole-mount carmine and histological staining within 6 weeks after injection, 32 the formation of invasive tumors in TREX1 KO-injected mice was greatly reduced for up to 8 33 weeks (Fig. 6A, B). This phenotype was comparable to the reduced invasive potential of 34 Membrane Type I (MT1)-MMP (MMP14)-deficient DCIS cells that we previously reported using 35 36 this model (Lodillinsky et al., 2016). The proliferation rates of parental DCIS and TREX1 KO clones were similar in vitro (Fig. S6M). Additionally, analysis of parental and TREX1 KO tumor 37 xenografts revealed no differences in the fraction of cells positive for the proliferation marker 38 Ki67 (Fig. 6C). Parental tumors displayed a significantly larger percentage of yH2AX-positive 39 nuclei than TREX1 KO tumors (Fig. 6 C-D). The fraction of cells with high and very high Z-40 scores was reduced at the margin of TREX1 KO tumors, but not in the tumor bulk (Fig. 6 E, F 41 and S6N). Overall, these results suggest that the transition from in situ to the invasive stage is 42 favored in WT cells by TREX1-dependent DNA damage occurring in deformed and ruptured 43 nuclei as the tumor grows in the confined environment of the mammary ducts. 44

We also asked whether NE ruptures can be seen in the mice xenograft and in the human tumor as well. We first used a combination of Lamin A/C and DAPI staining and looked for chromatin herniations, i.e. interruptions of the Lamin A/C staining with a protrusion of chromatin labelled by DAPI. We were able to find several such instances in the intraductal tumor xenografts (Fig. 7A), which correlated with nuclei positive for γ H2AX staining. Second, we used a combination of cGAS and DAPI staining. In mouse xenografts, we found regions enriched with the typical

cGAS perinuclear accumulation, corresponding to γ H2AX-positive nuclei (Fig. 7B). 1 Immunohistochemistry provided even clearer examples of NE ruptures, with cGAS staining at 2 3 the periphery of nuclei (Fig. 7C). Of note, the cGAS antibody was validated in vitro on DCIS cells depleted for cGAS (Fig. S7A). Human breast cancer samples displayed heterogenous 4 cGAS labelling and cGAS positive micro-nuclei, but we could also detect numerous NE rupture 5 6 events (Fig. S7B). A complete proof of the role of NE ruptures and TREX1 in human breast tumors will require deeper investigation of a larger number of patient samples. These 7 observations show that NE rupture events occur in vivo, both in DCIS tumor xenografts and in 8 9 human tumors and that cGAS staining has the potential to be a powerful tool to visualize the 10 occurrence of NE rupture events in tumor samples.

11 Discussion

TREX1 is a cytoplasmic exonuclease, mostly found associated with ER membranes (Lee-12 Kirsch et al., 2007a, 2007b), and shown to protect cells from the accumulation of cytoplasmic 13 DNA, either from viral or endogenous origins (Mazur and Perrino, 2001; Stetson et al., 2008). 14 15 Although TREX1 has already been proposed to act on nuclear DNA as well (Chowdhury et al., 2006; Maciejowski et al., 2015, 2019), possibly in conjunction with an endonuclease 16 (Chowdhury et al., 2006), to generate DSBs, there is so far no clear mechanism explaining 17 18 how TREX1 could act on nuclear chromatin. ROS and irradiation have been shown to induce 19 TREX1 nuclear translocation, although the precise mechanisms remain elusive (Chowdhury et al., 2006; Martinvalet et al., 2005; Yang et al., 2007). Based on our imaging and rescue 20 experiments, we speculate that TREX1 translocation could potentially implicate fusion of the 21 22 outer and inner nuclear membranes upon NE ruptures. This could allow ER proteins, by diffusion on the membrane, to gain access to the inner nuclear membrane and potentially to 23 24 the poorly characterized intranuclear membrane networks of the nuclear reticulum (Malhas et 25 al., 2011). It is likely that the whole ER-bound SET complex transfers to the inner nuclear 26 membrane upon NE rupture events. The SET complex has previously been implicated in the induction of TREX1-dependent nuclear DNA double strand breaks (Chowdhury et al., 2006). 27 In agreement, we did not observe any transient formation of single strand breaks upon 28 confinement, using RPA-GFP, which displays DNA damage foci upon treatment with 29 hydroxyurea (Fig. S7C). We thus speculate that DNA damage after NE rupture could also 30 implicate other members of the SET complex that, together with the TREX1 exonuclease, gain 31 32 access to inner nuclear membranes due to fusion of the outer and inner nuclear membranes at sites of rupture. 33

In the model systems we studied here, the ATM-dependent DNA damage response pathway 34 35 is involved both in the senescence phenotype in RPE1 cells, and in the induction of the collagenolytic response in the senescence-deficient DCIS cell line. This is in contrast to the 36 cGAS-dependent inflammatory pathway, which does not seem to be required (Harding et al., 37 2017; Liu et al., 2018). A potential effect of ATM activation by DNA damage is a cell-cycle 38 arrest. We indeed found that doxo-treated DCIS cells showed a reduction of cells in S/G2 upon 39 48 hours of treatment (Fig. S7D). Nevertheless, this cell cycle arrest per se does not explain 40 41 the increase in collagen degradation as this response was not increased comparing cells in G1 versus S/G2 (Fig. S7E). Two recent studies pointed to a potential activation of an EMT-like 42 43 phenotype downstream of ATM activation (Jiang et al., 2019; Peng et al., 2019). Furthermore, several ATM substrates have also been associated with lysosomal activity and thus potentially 44 to collagen degradation (Kang et al., 2017). Our results suggest that upon chronic, sub-lethal 45 46 levels of DNA damage, cells that have lost the normal ATM-dependent senescence-associated proliferation arrest, could initiate a partial EMT program including an invasive behavior, driving 47 the transition from *in situ* to invasive carcinoma stages. 48

A recent study (Shah et al., 2021) found that DNA damage can be triggered by confinement independently of NE rupture events some cell lines, including MDA-MB-231 cells. We thus assayed these cells and found that DNA damage upon confinement was both NE rupture- and TREX1-independent (Fig. S7G, H). These results suggest that tumors might be differentially sensitive to TREX1 inhibition.

6 Our experiments do not prove that TREX1 is the main driver of DNA damage in the human 7 desease nor that DNA damage associated with nuclear deformation plays a role in the human 8 disease progression. TREX1 has been described to promote pro- or anti-tumoral effects 9 depending on different cellular and tumoral contexts (Benci et al., 2019; Erdal et al., 2017; Vanpouille-Box et al., 2017). To get further insight into this question, we analyzed the 10 association of TREX1 expression levels in breast cancer with overall survival using public 11 datasets. This analysis revealed that high level of TREX1 expression is significantly associated 12 with reduced probability of survival (Fig. S7F). Thus, targeting this exonuclease might be an 13 effective therapeutic strategy to curb tumor progression, while promoting anti-tumoral immune 14 response via cGAS activation (Stetson et al., 2008; Takahashi et al., 2018). 15

In this study, we focused on mammary tumors, but nuclear envelope ruptures could also occur in other tumors. As a proof of concept, we performed cGAS staining on colorectal tumor samples. In 2 patients out of 4 tested, we observed a good correlation between regions highly enriched in nuclei positive for γH2AX, which corresponded to the invasive front of the tumor, and regions with a high fraction of nuclei with NE rupture events (Fig. S7 I, J and K). A broader study is needed to assess whether our findings can be extended to other tumor types.

22 We and others have shown that the NE is a fragile barrier constantly being challenged in 23 physiology and disease (Denais et al., 2016; Raab et al., 2016; Srivastava et al., 2021). The occurrence of DNA damage associated with nuclear deformations is likely to be a common 24 phenomenon. In normal tissues, this would trigger cellular senescence, contributing to 25 26 developmental programs and tissue homeostasis, or even participating in tissue aging. In contrast, in tumor cells, in which the senescence checkpoint has been lost, it would lead to an 27 28 aberrant invasiveness in the absence of a proliferative arrest, promoting tumor growth and 29 invasion.

30 Limitations of the study

31 Double labelling with fluorescent 53BP1 and icGAS in live cells unambiguously demonstrated 32 the causal relationship between NE rupture events and DNA damage; But the different dynamics of icGAS entry and exit from the nucleus, and DNA damage foci appearance and 33 repair, generate a more complex set of situations when considering cells at a fixed time point, 34 or fixed cells stained with these two proteins by immunofluorescence. This difficulty is 35 36 exacerbated in 3D samples in which NE rupture events can happen out of the plan of imaging. In cases in which a direct live observation of the rupture events is difficult, for example in slices 37 38 of tumor samples or in the duct on chip assay, cells in which cGAS perinuclear accumulation and DNA damage are simultaneously present likely represent only a subset of the cells that 39 40 have undergone NE rupture dependent DNA damage, making precise quantification difficult.

41 Acknowledgements:

We thank the flow cytometry and cell sorting facility, the animal facility at the Institut Curie and the microscopy facility of IPGG for equipment and technical assistance. We thank Titia de Lange and John Maciejowski for providing the guideRNA to generate the TREX1 KO CRISPR cell lines, John Maciejowski, Alexis Lomakin and Ana-Maria Lennon-Dumenil, for suggestions during the writing of this manuscript, Nicolas Carpi for lab management, plasmid amplifications and computer technical support, Juan-Manuel Garcia Arcos for help in assembling the figures

and drawing the graphical abstract, Aastha Mathur for data analysis of the yH2AX-positive 1 nuclei relative to the xenograft edge, Zahraa Alraies for the preparation of cDNA samples for 2 the quantitative RT-PCR analysis, Dipanjan Bhattacharya who developed the method to 3 automatically segment nuclei at IFOM, Dr. Ines Ferrara for providing technical support for the 4 human tumor samples. Finally, we also thank the patients and their families who contributed 5 tissue samples to these studies. This study was supported by the following grants: Institut 6 Pierre-Gilles de Gennes-IPGG (Equipement d'Excellence, "Investissements d'avenir", 7 program ANR-10-EQPX-34) and laboratoire d'excellence, "Investissements d'avenir" program 8 ANR-10-IDEX-0001-02 PSL and ANR-10-LABX-31; Laboratory of Excellence (LabEx) 9 CelTisPhyBio ANR 11-LABX-0038 to SAG; Plan Cancer 2018 'Single Cells' (19CS007-00) to 10 FR; Fondation pour la Recherche Médicale (FDT20160435078) to CC; Associazione Italiana 11 per la Ricerca sul Cancro (AIRC-IG#18621 to GS, AIRC-0IG#22145 to CT, and 5XMille #22759 12 to GS and CT); the Italian Ministry of University and Scientific Research (MIUR) to GS (PRIN: 13 Progetti di Ricerca di Rilevante Interese Nazionale - Bando 2017#2017HWTP2K); Institut 14 National du Cancer INCA 7905 (MetaCLEM) and INCA PLBIO 2019-1-PL BIO-07-ICR-1, 15 INSERM Plan Cancer Single Cell grant 19CS007-00, Fondation ARC pour la Recherche 16 contre le Cancer (PGA1 RF20170205408) and institutional funding from Institut Curie and 17 Centre National de la Recherche Scientifique to PC; ERCadg CellO (FP7-IDEAS- ERC-18 19 321107) to JLV; LABEX DCBIOL (ANR-10-IDEX-0001-02 PSL and ANR-11-LABX-0043), ANR ANR-17-CE15-0025-01 and ANR-18-CE92-0022-01 to NM; INCA PLBIO 2019-1-PL BIO-07-20 ICR-1, INSERM Plan Cancer Single Cell grant 19CS007-00 to MP, NM and PC, Italian 21 Foundation for Cancer Research (AIRC) Accelerator Award ID. 24296 to CT. This work was 22 supported in part by grants from Région Ile-de-France. 23

24 Author Contributions

G.P.F.N. designed and performed the experiments, analyzed and interpreted the data and 25 wrote the manuscript. S.A-G. and G.P.F.N. performed the 3D collagen degradation assays. 26 S.A-G, A.Y., C.V., P.C. and J-L.V. designed the duct-on-chip device. F.R. and E.L. performed 27 the mouse xenograft assays and S.A-G., F.R. and G.P.F.N. analyzed the data. M.Gr. 28 29 performed the sequencing of the TREX1 CRISPR clones and generated some stable cell lines. M.M. wrote Image J macros for data analysis and helped on data interpretation. A.W. 30 31 performed and quantified the experiments with DCIS cells expressing geminin-mCherry. The R.N.R. and J.G. designed and performed multiplex IF and IHC on mice xenografts samples 32 and IHC on human tumor samples. A.P. performed the quantitative RT-PCR analysis. C.C. 33 34 analyzed data relative to the cell division cycle. M.G. generated stable cell lines and performed molecular cloning. C.L. provided images of mouse xenografts for analysis. V.C. and C.T. 35 performed and interpreted the assays involving human primary tumors. G.S. designed, 36 supervised and interpreted the assays involving human primary tumors and edited the 37 manuscript. P.C. designed, supervised and interpreted the mouse xenograft assays and edited 38 the manuscript. N.M. conceptualized the role of TREX1, helped designing and interpreting 39 40 experiments, supervised M.Gr. and edited the manuscript. G.P.F.N., S.A-G., M.P., P.C., N.M. and G.S. actively engaged in discussions throughout the study. M.P. supervised the study, 41 designed the experiments, interpreted the data and wrote the manuscript. 42

43

44 **Declaration of Interest.**

45 Matteo Gentili, Nicolas Manel and Matthieu Piel are authors of a patent entitled 'Method to 46 monitor and quantify interphase nuclear envelope rupture events ', WO2017140875A1

47 Main Figures Titles and Legends:

Figure 1. Human breast tumor and mouse xenograft model of breast cancer progression 1 display strong nuclear deformation and DNA damage. (A) Immunohistochemistry of in situ 2 advanced human primary breast tumors. RAB5A (red), vH2AX (brown). Bar, 80 µm. (B) 3 4 Magnified region of in situ advanced primary breast tumor with a micro-invasive focus. Yellow arrowheads point to deformed nuclei. Bar, 25 µm. Box and whisker plot showing the median 5 value and 10-90 percentiles of (C) nuclear roundness index or (D) yH2AX-positive nuclei. (E) 6 7 Bars are the mean ± SD of 6 individual tumor samples where at least 150 nuclei were scored 8 per sample. (A-D) Representative of 7 independent tumor samples where 21 and 27 nuclei 9 were analyzed for tumor bulk and micro-invasive focus, respectively, per sample. (F, G) Immunofluorescence analysis of alpha-smooth muscle actin (green), human-specific KU70 10 11 (cyan) and yH2AX (red) in 7 weeks old mouse xenografts at different stages generated by intraductal injection of DCIS cells. (F) The in situ-advanced stage is characterized by a 12 discontinuous/broken myoepithelial layer. Graph, box and whisker plot showing the median 13 14 value and 10-90 percentiles of yH2AX-positive nuclei measured at in situ-early and -advanced stages. Data represents 3 independent experiments where 500 nuclei were scored per tumor 15 stage, per experiment. (G) Invasive stage: SMA-positive and elongated cells represent cancer 16 associated fibroblasts. Graph, box and whisker plot showing the median value and 10-90 17 percentiles of the nuclear roundness index measured at invasive and In situ stages (divided 18 19 into edge-up to 2 cell layers below the myoepithelial layer, and bulk). Data represents 3 independent experiments where 7 In situ and 13 invasive tumor samples were analyzed (for a 20 total of 140 nuclei analyzed for In situ-bulk, 139 nuclei analyzed for In situ-edge and 264 nuclei 21 22 analyzed for invasive tumor samples). (F, G) Bar, 100 µm, (G) Zoom Bar, 50 µm; Inset Bars, 15 µm. (H) Classification of Z scores categories (yH2AX intensities) of nuclei as a function of 23 different distances from the tumor edge (determined by the myoepithelial layer) (for details 24 25 refer to fig. S1A). Data represents a total of 23 images analyzed for DCIS parental tumors from 3 independent mice injections. (I) Duct-on-chip assay. Cell density was measured by counting 26 the number of cells/µm² in 5 random fields (20x magnification) at the indicated time points and 27 28 are expressed in the graph relative to the 24h time point. Data represents the mean \pm SD of 3 independent experiments. Bar, 50 µm; Zoom Bar, 25 µm. (J-L) Duct-on-chip assay. DCIS cells 29 stably expressing 53BP1-mCherry and cGAS-EGFP were injected into the duct-on-a chip 30 device at low and high density. Nuclear roundness (J), DNA damage (K) and NE rupture (L) 31 were assessed. Graphs: (J) Box and whisker plot showing the median value and 10-90 32 percentiles of the nuclear roundness. (K, L) Bars are the mean ± SD of 3 independent 33 experiments. P values were calculated by unpaired Student's t-test, except for items "E" and 34 "K" (One-way ANOVA with post hoc Tukey test) and item "L" (Chi-square test). ***P < 0.0001; 35 36 **P < 0.005; *P < 0.05; ns = not significant. See also Fig.S1 and Movie S1

Figure 2. Strong confinement induces NE rupture. (A) Cells stably expressing 53BP1-37 EGFP and catalytically inactive cGAS-mCherry (icGAS) were confined and images were taken 38 after 2 h. Bar, 5 µm. (B) Single cell curves of 53BP1 foci number as a function of time in cells 39 displaying or not NE rupture while under 2 µm confinement. (C) Quantification of DNA damage 40 level during confinement. Data represents the mean ± SD of 4 independent experiments where 41 20 cells per experiment per condition were analyzed. (E) Quantification of the percentage of 42 cells displaying more than 3 53BP1 foci/nucleus while confined at 2 µm. (F) Frequency 43 distribution of 53BP1 foci number/nucleus in cells displaying NE rupture. Data represents 250 44 45 nuclei pooled from 3 independent experiments. (G) Illustrative panels depicting the appearance and repair of DNA damage foci in cells stably expressing 53BP1-EGFP while 46 confined at 2 µm. Bar, 5 µm. (H, I) Frequency of foci appearance and foci life-time (foci 47 duration) in RPE1 cells confined at 2 µm or treated with etoposide (25 µM). Box and whisker 48 plot show the median value and 10-90 percentiles of 3 independent experiments where 20 49 cells per condition per experiment were analyzed. (J) Cells stably expressing 53BP1-EGFP 50

and icGAS were plated on glass bottom dishes and imaged for several hours. Arrows point to 1 NE rupture events. (K) Single cell curves showing the relationship between NE rupture and the 2 appearance of 53BP1 foci. (L) Box and whisker plot showing the median value and 10-90 3 percentiles of the ratio between the number of 53BP1 foci after and before NE rupture. Data 4 are from 2 independent experiments where 10 NE rupture events per experiment were 5 analyzed. (M) Cells stably expressing 53BP1-EGFP and icGAS were confined at 2 µm, 6 harvested and plated for 20 minutes before fixation for immunostaining with antibodies against 7 8 GFP (left) or yH2AX (right); box and whisker plot show the median value and 10-90 percentiles. P values were calculated by unpaired Student's t-test, except for items "H" and "I" (One-way 9 ANOVA with post hoc Tukey test). ***P < 0.0001; **P < 0.005; ns = not significant. See also 10 11 Fig.S2 and Movies S2, S3

Figure 3. DNA damage upon NE rupture is TREX1-dependent. (A, B) A variety of TREX1-12 deficient or -proficient cells was confined at 2 µm and DNA damage level was assessed after 13 2 h under confinement. Graphs represent the mean ± SD of 3 independent experiments where 14 20 cells were analyzed per condition per experiment. Western blots: TREX1 depletion 48h 15 post-knockdown; tubulin is the loading control. Bar, 10 µm. (C) Box and whisker plot showing 16 17 the median value and 10-90 percentiles of the ratio between the number of 53BP1 foci after 18 and before NE rupture in siRNA-treated cells. Data are from 2 independent experiments where 15 cells per experiment were analyzed. (D) Immuno-gold electron microscopy images of RPE1 19 TREX1 KO cells reconstituted with TREX1-mCherry, confined at 2 µm or left unconfined. Bar, 20 0.5 µm; magnified regions bar, 0.1 µm. (E) Number of mCherry (TREX1) immune gold particles 21 at the indicated cellular compartments, see also Fig. S5C. The 'cytoplasm' compartment also 22 includes particles associated to cytoplasmic endomembranes like ER and MVBs. P values 23 were calculated by One-way ANOVA with post hoc Tukey test, except for item "C", which was 24 calculated by unpaired Student's t-test. *P < 0.05; ***P < 0.0001; ns = not significant. In panel 25 E, statistical significance was calculated by chi-square test; *** does not refer to P value but 26 significance according to the chi-square statistics (see Table S1). See also Fig.S3, S4 and 27 28 Movie S4

29 Figure 4. Long-term, strong confinement causes TREX1-dependent cell senescence. (A) Cells stably expressing catalytically inactive cGAS were confined at 2 µm for 3 or 12 h. Cells 30 31 were then harvested and replated for imaging for cell cycle duration assessment in cells displaying or not NE rupture. Graph, left: box and whisker plot showing the median value and 32 10-90 percentiles of the cell cycle duration. Data for 3 h of confinement represents 3 33 34 independent experiments where a total of 150 cells with non-ruptured and 200 cells with ruptured nuclei were analyzed. Data for 12 h of confinement represents 3 independent 35 experiments where a total of 23 lineages with non-ruptured and 40 lineages with ruptured 36 nuclei were analyzed. Right: Frequency distribution of the number of cell divisions. (B, C, F, 37 G) siRNA-treated cells were confined, then harvested, replated and cultured for 72 h before 38 fixation for β -gal staining (B, C) or immunostaining of heterochromatin foci (HP1y) (F, G). (C) 39 40 Data represents the mean ± SD of 3 independent experiments where 200 cells were scored per condition per experiment. (D) Cells were confined for 3 or 12 h at 4 or 2 µm; cells were 41 then harvested and replated for 72 h before lysis for western blot; tubulin is the loading control. 42 (E) RPE1 TREX1 KO cells or RPE1 TREX1 KO cells reconstituted with TREX1 WT-mCherry 43 were confined at the indicated heights for 12 h. Cells were then harvested, replated and 44 45 cultured for 72 h before lysis for western blot; tubulin is the loading control. Western blots are representative of 2 independent experiments. Bars, 80 µm (B) and 10 µm (F). P values were 46 calculated by unpaired Student's t-test (A) or One-way ANOVA with post hoc Tukey test (C, 47 G). ***P < 0.0001; **P < 0.005; ns = not significant. See also Fig.S5 48

Figure 5. TREX1-dependent DNA damage leads to collagen degradation and invasion. 1 (A, B, C) Duct-on-chip assay. (A) DCIS cells stably expressing 53BP1 and catalytically inactive 2 cGAS were transiently depleted for TREX1 and 48 h later injected in the chip device. Graphs, 3 4 data represents the mean \pm SD of 3 independent experiments where 5 random fields (at 20x magnification) were scored per condition per experiment. Bar, 50 µm; zoom Bar, 10 µm. (B) 5 DCIS cells were transiently depleted for TREX1 and 48 h later injected in the same chip device 6 with siControl cells (labeled with a green cell tracker). Graphs, (top) data represents the mean 7 8 ± SD of 4 independent experiments where cells invading from 7 random gates were scored per experiment; (bottom) frequency distribution histogram of the data displayed on the bar 9 graph. Bar, 50 µm. (C) DCIS cells stably expressing 53BP1-EGFP were pre-treated for 12 h 10 with doxorubicin (Doxo, 20 nM) and co-injected with DCIS cells stably expressing 53BP1-11 mCherry pre-treated for 12 h with DMSO. Data represents the mean ± SD of 2 independent 12 experiments where cells invading from 10 random gates were scored per experiment. Bar, 40 13 14 µm. (D) DCIS cells were confined for 2 h. Following the confinement period, cells were harvested and embedded in 3D type I collagen for 12 h. Degraded collagen (red); DAPI (cyan). 15 (E) A variety of TREX1-deficient or -proficient DCIS cells was confined at the indicated heights. 16 Data represents 3 independent experiments where 50 cells per condition per experiment were 17 analyzed. (F) It was proceeded exactly as described in "D" except that the experiment was 18 19 performed with TREX1-depleted DCIS cells. Data represents 3 independent experiments where 60 cells per condition per experiment were analyzed. Data was normalized by the mean 20 of control samples. (G) It was proceeded exactly as described in "D" except that cells were 21 22 treated with ATM inhibitor (KU-55933, 10µM) or MMP inhibitor (GM6001, 40µM) while under confinement and in 3D collagen. Data represents 3 independent experiments where 60 cells 23 per condition per experiment were analyzed. All box and whisker plots show the median value 24 25 and 10-90 percentiles of the collagen degradation area. P values were calculated by unpaired Student's t-test (F), Chi-square test (A-right, B, C) or One-way ANOVA with post hoc Tukey 26 test (E, G). ***P < 0.0001; ns = not significant. See also Fig.S6 and Movie S5 27

Figure 6. TREX1-dependent DNA damage promotes tumor invasion in mouse xenograft 28 29 model of breast cancer. (A) Left: Immunofluorescence analysis of alpha-smooth muscle actin, SMA (green) and DAPI (cyan) in 6-8 weeks old mouse xenografts generated by 30 31 intraductal injection of either parental DCIS cells or TREX1 KO clones. Bar, 100 µm. Middle: 32 whole-mount carmine-stained 7 weeks-old glands. Bar, 1 mm. Right: Hematoxylin & Eosin stained 7 weeks-old glands. Bar, 60 µm. (B) Classification of the tumor xenograft stage 6-8 33 weeks post-intraductal injection of either parental DCIS cells or TREX1 KO clones from 3 34 independent mice injections. Data represents a total of 7 glands scored for DCIS parental 35 36 tumors and 14 glands for TREX1 KO tumors (TREX1 KO #1 +TREX1 KO #2 clones). (C) Scatter dot plots of vH2AX- and Ki67-positive nuclei (lines are median) 6-8 weeks post-37 intraductal injection. A total of 13 parental and 34 TREX1 KO (18 TREX1 KO #1 + 16 TREX1 38 KO #2) images were analyzed for Ki67 scoring; a total of 31 parental and 62 TREX1 KO (35 39 TREX1 KO #1 + 27 TREX1 KO #2) images were analyzed for yH2AX scoring. (D) 40 Immunofluorescence analysis of yH2AX (red), alpha-smooth muscle actin (green) and DAPI 41 (cyan) in 6-8 weeks old mouse xenografts generated by intraductal injection of either parental 42 DCIS cells or TREX1 KO clone. Blue arrowheads point to DNA damage-yH2AX-positive cells; 43 yellow arrowheads point to mitotic or apoptotic figures. Bar, 40 µm. (E, F) Z score categories 44 (yH2AX intensities, see Methods and fig. S1A) of nuclei localized in the tumor bulk (E) or in 45 the tumor edge (determined by the myoepithelial layer) (F). Data represents a total of 23 46 images analyzed for DCIS parental tumors and 30 images for TREX1 KO tumors (TREX1 KO 47 #1 +TREX1 KO #2 clones) from 3 independent mice injections. P values were calculated by 48 unpaired Student's *t*-test, ***P < 0.0001; *P < 0.05; ns = not significant. See also Fig.S6 49

Figure 7. Mouse tumor xenografts display NE rupture and DNA damage. (A)
 Immunofluorescence analysis of laminA/C (green), DAPI (cyan) and γH2AX (red). Bar, 25 μm;
 inset bars, 5 μm (single channels) and 3 μm (merged channels). (B) Multiplex
 immunofluorescence analysis of cGAS (green), DAPI (cyan) and γH2AX (red). Bar, 60 μm. (C)
 cGAS immunohistochemistry (brown) and nuclei (blue). Bar, 25 μm. All analysis was
 performed in mouse xenografts at *in situ*-advanced stage generated by intraductal injection of
 DCIS cells. Yellow arrowheads point to NE rupture events. See also Fig. S7

1 STAR Methods

2 3

4 5

6 7

8

9

14

16 17

18

19 20

21

22

23

RESOURCE AVAILABILITY

Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Matthieu Piel (<u>matthieu.piel@curie.fr</u>)

10 Materials Availability

All newly generated materials associated with this study (stable cell lines and plasmids,
 design of microfabricated devices) will be provided upon request to the lead contact.

15 Data and Code Availability

- All data reported in this paper will be shared by the lead contact upon request
- All original code (Image J macros) has been deposited at Mendely data and is
- publicly available as of the date of publication. DOIs are listed in the key resources table.
 - Any additional information required to reanalyze the data reported in this manuscript is available from the lead contact upon request.

24 EXPERIMENTAL MODEL AND SUBJECT DETAILS

25 26 **Mice**

27

Animal care and use for this study were performed in accordance with the recommendations of the European Community (2010/63/UE) for the care and use of laboratory animals. All animal experimental procedures were approved by ethics committee of Institut Curie CEEA-IC #118 (Authorization APAFiS #24649-2020031220398710-v1 given by National Authority) in compliance with international guidelines. As research was limited to the mammary gland, all transplanted animals were female mice.

- 34
- 35 Intraductal transplantation method
- 36

Eight to ten week-old virgin female CB17/Icr-Prkdc^{scid}/IcrIcoCrI mice (Charles River Laboratories) were anesthetized by inhalation with isoflurane and intraductally injected into the 3rd and the 4th pair of glands with 2 μl PBS containing 50,000 MCF10DCIS.com cells as previously described (Behbod et al., 2009; Lodillinsky et al., 2016). Five to eight weeks after injection with no additional manipulation, mice were sacrificed and the engrafted mammary glands were harvested and processed for whole-mount and histological and IHC staining on tissue sections.

45 Human tissues

46

Human breast cancer tissue samples were collected according to the Helsinki Declaration and the study was approved by the University of Palermo Ethical Review Board (approval number 09/2018). The cases were classified according to the World Health Organization classification criteria of the tumors of the breast. All the tissue samples were from 7 adult female patients with breast ductal adenocarcinoma with an age range between 40 and 88 years old (histotypes *in situ* ductal adenocarcinoma, invasive ductal adenocarcinoma or both).

- 53
- 54 Human Cell lines

1 2 Cell lines are described in the Key Resources Table. MCF10DCIS.com and MDA-MB-231 cell lines were kindly provided by the lab of Dr. Philippe Chavrier (Institut Curie, Paris, France). 3 MCF10DCIS.com cells were culture in Advanced DMEM- F12 (GIBCO) medium supplemented 4 5 with 2 mM glutamine, 5% horse serum and 1% penicillin and streptomycin (GIBCO #15140-122). MDA-MB-231 was maintained in L-15 culture medium (Sigma-Aldrich, St Louis, MO, 6 7 USA) with 2mM glutamine (GIBCO, Cergy Pontoise, France) and 15% fetal bovine serum (GIBCO). MCF10A cells were culture in DMEM-F12 (GIBCO) supplemented with EGF 8 (20ng/ml) (Peprotech #AF-100-15), hydrocortisone (0.5µg/ml) (SIGMA #H0888), cholera toxin 9 (100ng/ml) (SIGMA #C8052), Insulin (10µg/ml) (SIGMA #I9278), 5% horse serum and 1% 10 penicillin and streptomycin. RPE1 cells were grown in DMEM-F12 Glutamax medium (GIBCO), 11 supplemented with 10% FBS and 1% penicillin and streptomycin (GIBCO). All cells were 12 13 maintained at 37 °C in 5% CO₂, with the exception of MDA-MB-231 cells, which were 14 maintained at 37 °C in 1% CO₂.

15

16 METHOD DETAILS

17

18 Constructs

19

The following constructs were kindly provided by the laboratory of Dr. Nicolas Manel (Institut 20 Curie, Paris, France): pTRIP-CMV-mCherry-TREX1 WT and D18N were cloned from pEGFP-21 C1-TREX1 (Addgene #27219). pTRIP-SFFV-EGFP-FLAG-cGAS E225A/D227A and pTRIP-22 23 CMV-mCherry-FLAG-cGAS E225A/D227A are described elsewhere (Gentili et al., 2019; 24 Raab et al., 2016). pTRIP-SFFV-EGFP-53BP1 (amino acids 1224-1716 for isoform 1) was obtained by cloning from pTRIP-CMV-mCherry-53BP1 (Gentili et al., 2019). The following 25 26 constructs were provided byb the laboratory of Dr. John Maciejowski (MSKCC, New York, USA): pLENTI-CMV-GFP-TREX1 deltaC (aa1-235), pLENTI-CMV-GFP-TREX1 deltaC-27 sec61TM and pQCXIP-GFP-RPA70 (Mohr et al., 2021). 28 29

30 Lentiviral particles production in 293FT cells and Lentivector transductions

31

Lentiviral particles were produced as previously described from 293FT cells (Lahaye et al., 2013). Lentiviral viral particles and viral-like particles were produced by transfecting 1µg of psPAX2 and 0.4µg of pCMV-VSV-G together with 1.6µg of a lentiviral vector plasmid per well of a 6-well plate. For cell transduction, 0.5x10⁶ cells were plated in a 6 well plate in 1ml and infected with 2ml of fresh lentivector in the presence of 8µg/ml of Protamine.

38 Quantitative RT-PCR analysis

39

40 Total RNA was extracted using the RNeasy Mini kit (Qiagen) and guantified by NanoDrop to assess both concentration and quality of the samples. Reverse transcription was performed 41 using the SuperScript VILO cDNA Synthesis kit from Invitrogen. Gene expression was 42 analysed by using the TagMan Gene expression Assay (Applied Biosystems). 0.1 ng of cDNA 43 was amplified, in triplicate, in a reaction volume of 25 µl with 10 pmol of each gene-specific 44 primer and the SYBR Green PCR MasterMix (Applied Biosystems). Real-time PCR was 45 performed on the 14 ABI/Prism 7700 Sequence Detector System (PerkinElmer/Applied 46 Biosystems) using a pre-PCR step of 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C 47 and 60 s at 60 °C. Specificity of the amplified products was confirmed by melting curve analysis 48 (Dissociation Curve TM; Perkin Elmer/Applied Biosystems) and by 6% PAGE. Preparations 49 50 with RNA template without reverse transcription were used as negative controls. Samples were amplified with primers for each gene (for details see the quantitative PCR primer list below) 51 and GAPDH as a housekeeping gene. The cycle threshold C_t values were normalized to the 52 GAPDH curve. PCR experiments were performed in triplicate and standard deviations 53 calculated and displayed as error bars. 54

1 2

cGAMP extraction with methanol/water

3 Cells were seeded and treated the day after with HT-DNA (1µg/ml) for 7h. 1.5x10⁶ cells were 4 5 recovered and washed with PBS. Cell pellets were resuspended in 80% methanol and frozen at -80°C. To perform cGAMP extraction, pellets were frozen/thawed five times in liquid nitrogen 6 (with vortexing steps between each cycle). Then the samples were centrifuged at 16000g for 7 8 20 min at 4°C. Supernatants were recovered and dried in a speed vaccum drying in Savant DNA Speed Vac DNA 110 for 3 h at 65°C. Pellets were resuspended in 150µl of DNAse/RNAse 9 10 sterile water. cGAMP concentration was obtained with the 2'3'-cGAMP ELISA Kit (Cayman Chemical) according the manufacturer instruction, cGAMP guantities were normalized to the 11 12 number of cells extracted.

13

14 Generation of TREX1 CRISPR clones

15 16 The guideRNA (gRNA) targeting TREX1 was kindly provided by the lab of Titia De Lange (Rockefeller University, New York, USA): gTREX1, 5'-GAGCCCCCCACCTCTC-(PAM)-3'. 17 gRNA plasmid was co-transfected into target cells with an hCas9 expression plasmid 18 (Addgene) by nucleofection (Lonza apparatus). 1x10⁶ cells were mixed with electroporation 19 buffer (freshly mixed 125 mM Na2HPO4, 12.5 mM KCl, 55 mM MgCl2 pH 7.75), 2 µg Cas9 20 plasmid, and 2 µg gRNA plasmid, transferred to an electroporation cuvette (BTX), and 21 electroporated with program U-017 for RPE-1 cells or program D-023 for MCF10DCIS.com 22 cells. Cells were then allowed to recover for 48 h before single cell FACs sorting into single 23 wells of a 96 wells plate for single clone amplification and selection. Successful CRISPR/Cas9 24 25 editing was confirmed by both Western blotting of the amplified cell colonies and analysis of 26 indel size (using the ICE analysis toolbox (https://www.synthego.com/products/bioinformatics/crispr-analysis). 27

29 Duct-on-a-chip assay

30

28

Unlabeled type I collagen at 2.4 mg/ml (BD Biosciences, Cat. # 354236) was injected in the "collagen chamber" of the microfabricated duct-on-a-chip and incubated for 1h at 37°C. In the

meantime cells were ressuspended in matrigel (SIGMA #E1270) at a concentration of

 0.7×10^6 cells/µl and then 3 µl were injected in the "cells chamber". Images were acquired at

the desired time points after injection to assess cell invasion into the "collagen chamber".

36

37 Human primary tumor samples

38 Sections 2.5/3 micron-thick were cut from paraffin blocks, dried, de-waxed and rehydrated. The antigen unmasking technique was performed using Target Retrieval Solutions pH6 at 39 40 98°C for 30 min. After neutralization of the endogenous peroxidase with 3% H₂O₂ and Fc blocking by a specific protein block, double-marker immunohistochemistry was carried out by 41 incubation for 90 min at RT with the primary antibodies RAB5A (Abcam, 1:100, pH6) and 42 yH2AX (Abcam, 1:1000, pH6). Staining was revealed using Novolink Polymer Detection 43 Systems (Novocastra) and SuperSensitive Link-Label IHC Detection System Alkaline 44 Phosphatase (Biogenex). DAB (3,3'- diaminobenzidine) and Vulcan Fast Red were used as 45 substrate chromogens. The slides were counterstained with Harris hematoxylin (Novocastra). 46 47 All the sections were analyzed under a Zeiss AXIO Scope.A1 microscope (Zeiss, Germany) and microphotographs were collected using a Zeiss Axiocam 503 Color digital camera using 48 49 the Zen2 imaging software.

50 Immunohistochemistry and spectral multiplex (processed using Bond RX automated-

51 Leica)

Antibody reference: cGAS (D1D3G) Rabbit mAb #15102; Cell Signaling, Dilution: 1/50. Antigen
 retrieval: BOND Epitope Retrieval Solution 2 (Leica, AR9961; pH9) for 20 min; protein blocking:
 5 min (protein block serum-free Dako #X0909); incubation: 1h at room temperature

For DAB staining, once immunostaining finished, slides were counterstained with hematoxylin
before mounting with glycergel medium (Dako). Images were acquired using Digital Pathology
slide scanner (Nanozoomer 2.5, Hamamatsu). For multiplex IF, immunostaining was
processed with Opal[™] 7-Color IHC Kits (Akoya 23 Biosciences, NEL821001KT). HRP labelled
Rabbit Polymer and TSA opal fluorophores were incubated for 10 min each. Subsequently,
slides were submitted to DAPI staining for 10 min, washed and coverslipped with Prolong[™]
Diamond Antifade Mountant (ThermoFisher) before image acquisition.

- 11 Histological and immunofluorescence analysis of mouse tissue sections
- 12

Whole-mount carmine and hematoxylin and eosin staining were performed as described (Teuliere, 2005). To retrieve antigens on paraffin-embedded tissue samples, sections were incubated for 20 min in 10mM sodium citrate buffer, pH 6.0 at 90°C. Then, after 1h incubation in 5% fetal calf serum, sections were incubated overnight with diluted primary antibodies, washed and further incubated for 2h at room temperature with appropriate secondary antibodies.

20 Indirect immunofluorescence microscopy

21

Samples were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 for 5 min and then incubated for 1h at room temperature with primary antibodies. Following three washes with PBS, samples were incubated with the appropriate secondary antibodies for 1h at room temperature. Samples were again washed three times with PBS and mounted with Fluoromount G (Molecular probes).

28 **3D type I collagen degradation assay**

29

For collagen degradation assessment followed by immunofluorescence analysis, glass bottom 30 dishes (MatTek Corporation) were layered with 15 µl of a solution of 5 mg/ml unlabeled type I 31 32 collagen (IBIDI Cat. # 50201) mixed with 1/20-40 volume of Alexa Fluor 647-labeled collagen. Polymerization was induced at 37°C for 3 min and complete medium was added. Cells were 33 seeded onto the polymerized collagen layer and incubated for 1h at 37 °C. The medium was 34 35 then gently removed and two drops of a mix of Alexa Fluor 647-labeled type I collagen (10% 36 final) and unlabeled type I collagen at 2.4 mg/ml (BD Biosciences, Cat. # 354236) were added on top of the cells (top layer). After polymerization at 37 °C for 1.5h, 1 ml of medium added to 37 38 the MatTek dishes.

39

40 Transfection procedure and siRNA oligonucleotides

41

For RNA interference experiments, cells were transfected with siRNA oligonucleotides 42 (Dharmacon) using Lipofectamine® RNAiMAX reagent (Invitrogen) (RPE1 cells), or with 43 44 Lullaby (OZ Biosciences, France) (MCF10A cells, MCF10DCIS.com cells and MDA-MB-231 45 cells) according to manufacturer's protocol. The following SMARTpool siRNAs were used: human TREX1 (Dharmacon, cat. # L-013239-02-0005), human MB21D1 (cGAS) (Dharmacon, 46 cat. # L-015607-02-0005) and validated non-targeting siRNAs (Dharmacon, cat. # D-001810-47 48 10-20). Cells were analyzed 72 h post-transfection using standard Western blot or immunofluorescent analysis protocols. 49

50

51 Drug treatments

52

53 The following pharmacological inhibitors and chemical compounds were used: Etoposide 54 (DNA damaging agent, topoisomerase-II inhibitor; Cell Signaling, #2200), Doxorubicin (DNA

damaging agent, topoisomerase-II inhibitor; Cell Signaling, #5927), GM6001 (pan-inhibitor of 1 2 matrix metalloproteinases; Millipore, # CC1010), KU-55933 (ATM kinase inhibitor; Abcam, 3 #120637). 4

- Western blotting 5
- 6

7 Cells were collected and resuspended in Laemmeli buffer. Proteins were separated using 8 sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE, 4-20%) and transferred onto nitrocellulose or PVDF membranes. Membranes were blocked with 5% BSA 9 10 in Tris-buffered saline containing 0.05% Tween (TBS-Tween) for 1 h at room temperature, after which primary antibodies were added in TBS-Tween 5% BSA and incubated over night 11 at 4°C. The membranes were subsequently washed in TBS-Tween after which secondary 12 13 horseradish peroxidase conjugated antibodies (Jackson ImmunoResearch) were added in 5% 14 BSA in TBS-Tween and incubated for 1 h at room temperature. After extensive washing in TBS-Tween ECL signal was recorded on a ChemiDoc Touch Biorad Imager.

15 16

Microfabrication-based confinement

17 18

Confinement using the "6 well confiner": 19

To obtain large quantities of confined cells for cell population or biochemical studies, cell 20 confinement was performed using a version of the cell confiner adapted to multi-well plates 21 (Liu et al., 2015). To make the polydimethylsiloxane (PDMS, RTV615, GE) microspacers 22 (micropillars) at the desired height, 12 mm glass coverslips were plasma treated and then 23 placed on top of a PDMS mixture (10/1 w/w PDMS A / crosslinker B) on the wafer molds 24 (containing holes/micropillars, fabricated following standard photolithography procedures). 25 26 The height of the micropillars determines the height for spatial confinement of cells between the coverslip and the substrate. The surface of the confining side was always treated with non-27 adhesive pLL-PEG (SuSoS, PLL(20)-g[3.5]-PEG(2)). After baking at 95°C for 15 min, 28 29 coverslips with PDMS pillars were carefully removed from the wafers under isopropanol. They were then cleaned with isopropanol, well-dried, treated with plasma for 1 min, and treated with 30 0.5 mg/mL pLL-PEG in 10 mM pH 7.4 HEPES buffer for 1h at room temperature. Coverslips 31 with PDMS pillars were rinsed and incubated in medium for at least 2 hours before confining 32 the cells. The modified cover-lid of a multi-well plate was used to apply confining slides to cells. 33 34 In this case, large PDMS pillars were stuck on the cover-lid of the multi-well plate to hold the 35 confining slides containing a layer of microfabricated micropillars. These large PDMS pillars push the confining slides from the top of the plastic 6 well cover-lid to confine the cells in 6 well 36 37 glass/plastic bottom plates. The process of fabrication for these large pillars attached to the 6 well plate lid is as follows: the large PDMS pillars were fabricated by pouring a PDMS mixture 38 39 (A:B = 35:1) into a custom-made metallic mold, removing bubbles under vacuum, then baking overnight at 80°C, and getting the pillars out of the mold with the help of small amount of 40 41 isopropanol.

42 43 Live-cell imaging

44

45 Time-lapse recordings were acquired with 20x (NA 0.75) or 40x (NA 0.85) dry objectives using either an Eclipse Ti inverted microscope (Nikon) equipped with a Coolsnap HQ2 camera 46 47 (Photometrics) or with an spinning-disc confocal microscope with a Yokogawa CSU-X1 spinning-disc head on a DMI-8 Leica inverted microscope equipped with a Hamamatsu 48 OrcaFlash 4.0 Camera, a NanoScanZ piezo focusing stage (Prior Scientific) and a motorized 49 50 scanning stage (Marzhauser). Both microscopes were controlled by MetaMorph software (Molecular Devices). All microscopes were equipped with an on-stage incubation chamber 51 which maintained the temperature at 37°C and CO₂ concentration at 5% at all times. Image 52 53 analysis was performed using ImageJ/Fiji software (NIH, http://rsb.info.nih.gov/ij/index.html) or 54 MetaMorph software (Universal Imaging).

55

1 2

Measurements of yH2AX intensity relative to tumor edge in mice xenografts

For semi-automated analysis of nuclear yH2AX intensity in tissues as a function of distance 3 4 from tumor edge, a macro was written and run on Fiji software. First, individual nuclear regions 5 were obtained after thresholding using the DAPI channel. Subsequently, the tumor edge was 6 manually defined on the image using the myoepithelial layer as the reference. Next, a map of the distance to the tumor edge was obtained. Finally, yH2AX intensity and the distance to the 7 8 edge was measured for each nuclei of the tumor xenograft. Cells with strongly condensed 9 chromatin (as assessed by DAPI staining) were excluded from the analysis as they could be either mitotic or apoptotic cells. Due to intensity variation between experiments, yH2AX 10 intensities were normalized using Z scores. For each image, the distribution of the intensities 11 of nuclei inside the tumor (>30µm from the myoepithelial layer) and at the tumor edge (<30µm 12 13 from the myoepithelial layer) were fit using a Gaussian function to obtain an average nuclear 14 intensity and a standard deviation. Thus, individual nuclei intensities were normalized as: Z 15 score= (Nuclear Intensity-Average Nuclear Intensity)/Standard Deviation, to compare all 16 experiments.

17

18 Electron microscopy

Sample preparation, ultrathin cryo-sectioning and immunolabelling were performed as 19 previously described (Slot and Geuze, 2007). Briefly, RPE1 TREX1 KO + TREX1-mCherry 20 were confined at 2 µm for 30 min. Next, the confinement lid was removed (in order to have 21 enough number of cells for sample preparation, a total of twelve 6well plates were confined. 22 23 cells were harvested and pooled together). Cells were harvested and processed for fixation for 2h with 2% formaldehyde + 0.125% Glutaraldehyde in 0.1 M phosphate buffer pH 7.4. The 24 fixative was the replaced by PFA 1% in 0.1 M phosphate buffer and sample was stored at 4°C 25 in a sealed tube. For the preparation of the blocks cells were rinsed with PBS, the blocks were 26 27 embedded in 12% gelatin, cryoprotected with 2.3 M sucrose, and frozen in liquid nitrogen. 28 Ultrathin crvo-sections were cut on a Leica ultracut UC7 crvo-microtome and picked up in a 29 freshly prepared 1:1 mixture of 2.3 M sucrose and 1.8% methylcellulose, thawed and collected on formvar-coated grids. After washing with PBS containing 0.02 M glycine, sections were 30 incubated with primary antibody (anti-mCherry; GeneTex #GTX 128508 used at 1:250 dilution 31 32 and anti-PDI; EnzoLife Sciences ADI-SPA-891) and protein A-gold conjugates (PAG) (Utrecht University, The Netherlands). Sections were examined using a Tecnai Spirit electron 33 microscope (FEI Company) equipped with a digital camera Quemesa (SIS). Quantitative 34 35 Immuno EM analysis was used as described by (Mayhew, 2011). Approach 1: Testing for shifts 36 in compartment labelling in different groups of cells. This approach is used to test whether the 37 distribution of gold particles across compartments alters between not confined and 2 µm confined cells. The observed numerical frequency distributions of raw gold counts in different 38 39 groups of cells are compared directly by contingency table analysis. For a particular 40 compartment in a given cell, the number of expected gold particles is calculated by multiplying the corresponding column sum by the corresponding row sum and then dividing by the grand 41 row sum (see Table S1). Approach 2: Relative labelling index analysis, testing for differences 42 in specific-labelling enrichment of TREX1-mCherry gold particles between cellular 43 44 compartments. Labelling density values relate numbers of gold particles to the sizes of 45 compartments. For the relative labelling index analysis, a total of four compartments, including "nucleus", "peripheral ER", "inner nuclear membrane" and "outer nuclear membrane" were 46 selected to analyze the intracellular distribution of TREX1-gold particles. The expected 47 48 distribution was obtained by superimposing to pictures an array of points that was generated digitally, and points (P) were counted in the selected compartments. Pictures were taken 49 randomly with the only criterion of a well-preserved morphology. Gold particles on all sampled 50 fields were counted and named as observed gold particles (Ngo). For each compartment, Ngo 51 52 was compared with the expected numbers of gold particles (Nge, derived from the observed frequencies of points P). Labelling density (LD) is calculated as the number of gold particles 53 54 per test point (LD = Ngo/P). For each compartment, relative labelling index RLI = LD

compartment/LD cell. RLI=1 indicates random labeling while RLI>1 indicates when 1 2 compartments are preferentially labeled. By means of a two-sample Chi-squared (χ^2) analysis with two columns (*Ngo*) and (*Nge*) and *c* compartments (arranged in rows), two distributions 3 were compared, the total and partial x2 values were calculated, and whether to accept or reject 4 5 the null hypothesis was decided (of no difference between distributions) for c-1 degrees of 6 freedom. For any given compartment, the partial χ^2 is calculated as $(Ngo-Nge)^2/Nge$. If the 7 observed and expected distributions are different, examining the partial x2 values will identify those compartments that are mainly responsible for that difference. A convenient arbitrary cut-8 9 off is a partial $\chi 2$ value accounting for 10% or more of total (Mayhew, 2011).

10

11 QUANTIFICATION AND STATISTICAL ANALYSIS

12

Statistical analyses for all experiments were performed in Prism (GraphPad) v5.02. Statistical data are presented as median or mean ± SEM, SD or 10-90 percentiles. Sample size (n), statistical tests used and p-values are specified in the figure legends. Samples in most cases were defined as the number of cells counted/examined within multiple different fields of view on the same dish/slide, and thus represent data from a single sample within a single experiment that are representative of at least three additional independently conducted experiments.

20

1 Supplementary Figures Titles and Legends

2 Figure S1. The "duct-on-chip" device: reconstitution of the mammary duct using 3 microfabrication (related to Figure 1) (A) Schematic showing the nuclei segmentation and Z score transformation for the normalization of yH2AX intensities as a function of the distance 4 5 from the tumor xenograft edge (defined by the myoepithelial layer). Note that the great majority of nuclei with Z score > 2 are detected within the first 30 µm from the tumor edge/myoepithelial 6 7 layer. Cells with strongly condensed chromatin (as assessed by DAPI staining) were excluded 8 from the analysis as they could be either mitotic or apoptotic cells. Zoom bars, 5 µm. (B) 9 Density scatter plot of Z scores (yH2AX intensities) of DCIS parental tumors. Data represents a total of 23 images analyzed from 3 independent experiments (mice injections). (C) Diagram 10 illustrating the duct-on-chip device. A mixture of cells and matrigel is injected in the "cell 11 chamber" and type I collagen is injected in the collagen chamber. Subsequently, culture 12 medium is injected in the "medium chamber". Note that cells invade towards the collagen 13 14 chamber through 10 µm wide gates that recapitulate the breaches in the myoepithelial layer during in vivo of cell invasion. Bar, 80 µm. (D) DCIS cells were injected in the duct-on-chip in 15 the presence of DMSO (vehicle) or MMP pan inhibitor (GM6001, 40 µM). Cell invasion was 16 17 measured as distance from the gates. (E) Frequency distribution of invading cells as a function of the distance invaded from the gate. Data represents 3 independent experiments where cells 18 invading from 10 random gates (at 20x magnification) were analyzed per condition per 19 experiment. Bar, 60 µm. (G-I) Duct-on-chip assay. DCIS cells stably expressing 53BP1-20 mCherry and cGAS-EGFP were injected in the chip device at low (G) and high (H, I) densities. 21 Images were acquired at the indicated time points. (I) Nuclei displaying both NE rupture events 22 (discrete cGAS accumulation at the nuclear border) and augmented 53BP1 foci are shown. 23 24 Bars, 50 µm (F, G); 5 µm (H); zoom bars 20 µm (F), 10 µm (G). P value was calculated by Chi-25 square test in "E".

26

27 Figure S2. Characterization of nuclear envelope rupture under different confinement heights and of DNA damage following nuclear envelope rupture (related to Figure 2). (A) 28 29 RPE1 cells stably expressing catalytically inactive cGAS-EGFP (icGAS) were confined at the 30 indicated heights and images were acquired immediately after (and while cells were under confinement). Bar, 15 µm. (B) Quantification of NE rupture events as assessed by cGAS 31 perinuclear localization. Data represents the mean ± SD of 3 independent experiments where 32 50 cells per experiment per height were analyzed. (C) Frequency distribution of 53BP1-EGFP 33 34 (RPE1 cells, left) and 53BP1-mCherry (DCIS cells, right) mean intensities. (D) DCIS and MCF10A cells stably expressing 53BP1-mCherry and catalytically inactive cGAS-EGFP were 35 confined at 2 µm. Top: examples of cells displaying or not NE rupture events (note perinuclear 36 cGAS accumulation on cells displaying NE rupture). Bar, 10 µm. Bottom: quantification of DNA 37 38 damage levels following 2 µm confinement as assessed by the number of 53BP1 foci in cells displaying or not NE rupture. Data represents the mean of 3 independent experiments 39 40 (MCF10A cells) or 2 independent experiments (DCIS cells) where 20 cells per experiment per condition were analyzed. (E) Top: curves showing the 53BP1-EGFP mean intensity of RPE1 41 42 cells while under confinement at the indicated heights; data represents 4 independent experiments where 20 cells per experiment and per condition were analyzed. Bottom: curves 43 showing the 53BP1-EGFP total intensity (blue) and the average nuclear background intensity 44 (red) of RPE1 cells while under confined at 2µm. Data are pooled from 3 independent 45 experiments where a total of 50 cells per condition were analyzed. Bars are SD. (F) RPE1 cells 46 stably expressing catalytically inactive cGAS-EGFP (icGAS) were confined at 2 µm for 2 h; 47 48 subsequently, the confinement lid was removed, cells were harvested, replated for 20 minutes and fixed for immunostaining with the DNA damage markers RIF1 and yH2AX (red) and DAPI 49

(blue). Arrowheads point to cells with NE rupture, which are also positive for the DNA damage 1 markers analyzed. Bar, 20 µm. (G) Quantification of DNA damage foci at the indicated 2 conditions (DMSO, etoposide 25 µM and 2 µm, NE rupture). Images are representative of 2 3 independent experiments where 30 cells per experiment per condition were analyzed. Bars 4 represent the mean ± SD. (H) DCIS cells stably expressing Geminin-mCherry and 53BP1-5 EGFP were confined at 2 µm and the number of 53BP1 foci was assessed; box and whisker 6 plot shows the median value and 10-90 percentiles of 3 independent experiments where 20 7 8 cells per experiment per condition were analyzed. (I) RPE1 cells stably expressing 53BP1-EGFP were confined at 2 µm and imaged under spinning disc microscopy. White arrowhead 9 points to a non-ruptured NE bleb while the yellow arrowhead points to a bleb bursting event 10 that is followed by the appearance of DNA damage foci. (J) Graph showing the cumulative 11 number of new 53BP1 foci (red curve) following a bleb bursting event (assessed by an increase 12 in the cytosolic intensity of the probe 53BP1-EGFP, which leaks out of the nucleus upon NE 13 rupture, blue curve). Blue arrow indicates the instant of NE rupture/bleb bursting. P value was 14 calculated by unpaired Student's t-test in "H"; ns = not significant. 15

16

17 Figure S3. Characterization of DNA damage following nuclear envelope rupture in different cell lines and of TREX1 KO clones (related to Figure 3). (A) Diagrams illustrating 18 the Cas9/gRNA targeting sequence in the TREX1 gene and the primers used for the 19 20 sequencing of the TREX1 KO clones generated by CRISPR technology for RPE1 and DCIS cells. (B) Western blot of DCIS/RPE1 TREX1 WT and DCIS/RPE1 TREX1 KO clones; tubulin 21 is a loading control. (C) Single cell curves of 53BP1 foci number as a function of time in RPE1 22 cells (top) or DCIS cells (bottom) displaying NE rupture events while under 2 µm confinement. 23 (D) Top: MCF10A cells stably expressing 53BP1-EGFP and catalytically inactive cGAS-24 25 mCherry (icGAS) were transiently depleted for TREX1 with siRNA and 48 h later cells were confined at 2 µm. Bottom: Quantification of DNA damage levels during 2 µm confinement as 26 assessed by the number of 53BP1 foci in siTREX1 MCF10A cells displaying or not NE rupture. 27 Western blot shows TREX1 depletion 48 h post-knockdown; tubulin is the loading control. Data 28 29 represents the mean of 3 independent experiments where 20 cells per experiment per condition were analyzed. (E) Mean values of the ratio between 53BP1 foci SD mean intensity 30 31 and 53BP1 foci mean intensity (coefficient of variation of 53BP1 foci intensity) of RPE1 and DCIS cells transiently depleted for TREX1 and confined at 2 µm. This is an alternative way of 32 quantifying the increase in the number of 53BP1 foci in the nucleus, without counting the foci. 33 This globally measures the coefficient of variation of the signal, which increases when the 34 signal becomes less homogeneous. (F) Curves showing the 53BP1-EGFP mean intensity of 35 RPE1 and DCIS cells transiently depleted for TREX1 and confined at 2 µm. (E, F) Graphs 36 represent data pooled from 3 independent experiments for approximately 50 cells analyzed 37 per condition. (G) RPE1 cells stably expressing 53BP1-EGFP were transiently depleted for 38 TREX1 using siRNA and treated with etoposide (25 µM) for 2 h. Subsequently cells fixed and 39 40 stained for endogenous TREX1. Bar, 25 µm. (H) Frequency distribution of the number of nuclear blebs in RPE1 TREX1 KO clones and in parental RPE1 cells. Data represents 3 41 independent experiments where 60 cells per experiment were analyzed. (I) RPE1 cells 42 transiently transfected with TREX1-EGFP WT were confined at 2 µm using a pressure-43 controlled dynamic confiner. Images represent a single plane Z slice through the middle section 44 45 of the nucleus. Bars, 5 µm and 1 µm (magnification). Images are representative of 2 independent experiments. (J) Quantification of DNA damage levels (number of 53BP1 foci) in 46 DCIS wt cells and DCIS TREX1 KO #1 cells stably expressing 53BP1-mCherry reconstituted 47 with the indicated TREX1 constructs fused to GFP and confined at 2 µm. Quantification was 48 performed in cells displaying NE rupture. Data represents the mean ± SD of 3 independent 49 experiments where 25 cells per condition per experiment were analyzed. (K) Images showing 50

the distribution of TREX1 deltaC-GFP and TREX1 deltaC-Sec61TM-GFP in DCIS cells
 confined at 2 μm (note the diffuse distribution of TREX1 deltaC-GFP). Bar, 5 μm.

3

Figure S4. Characterization of DNA damage following spontaneous nuclear envelope 4 rupture and TREX1 localization by electron microscopy (related to Figure 3). (A, B) Left: 5 RPE1 cells stably expressing 53BP1-EGFP and catalytically inactive cGAS-mCherry were 6 transiently transfected with a non-coding siRNA (A) or with a siRNA targeting TREX1 (B), 7 plated on glass bottom dishes and imaged for several hours. Arrows point to NE rupture events 8 9 (note the accumulation of the cGAS signal at the rupture site). Right: curves showing the relationship between NE rupture and the appearance of 53BP1 foci (note that in TREX1-10 depleted cells 53BP1 foci number remains low following NE rupture events). Bars, 5 µm. (C) 11 12 Immuno-gold electron microscopy images of non-confined (top panels) and confined (2 µm, middle panels) RPE1 TREX1 KO cells reconstituted with TREX1-mCherry. Bottom panels: 13 14 non-confined RPE1 WT cells. Following confinement, cells were harvested and labeled with an antibody against mCherry to detect either transduced TREX1 (top and middle panels) or 15 non-specific labeling (negative control, bottom panels). Graph shows the quantification of the 16 17 relative labelling index (see methods for detailed explanation) of mCherry (TREX1) immune gold particles at the indicated cellular compartments. Bar, 0.5 µm; magnified regions bar, 0.1 18 µm. For Panel "C", refer to methods and Table S2 for the complete set of numbers and 19 20 statistics, *** does not stand for P value but significance according to the chi-square statistics. A total of 6 pictures from not confined (260 gold particles) and 9 pictures from 2 µm confined 21 cells (303 gold particles) were used for quantification. For other panels, P values were 22 calculated by One-way ANOVA with post hoc Tukey test in "J". **P < 0.005; *P < 0.05; ns = 23 not significant. See also Table S2 and Movie S4. 24

25

Figure S5. Long-term, strong confinement causes cell senescence in non-transformed 26 27 cells but not in cancer cells (related to Figure 4). (A) RPE1, MCF10A and DCIS cells were treated with doxorubicin (40 nM), etoposide (25 µM) or DMSO (vehicle) for the indicated 28 29 lengths of time. Cells were then fixed and processed for β -gal staining. The percentage of β gal-positive cells was plotted. Graph, data represents mean ± SD of 3 independent 30 experiments where 200 cells were scored per condition per experiment. (B) Frequency 31 distribution of the designated categories for cells under the indicated confinement heights. 32 Data represents 3 independent experiments where 37 non-confined cells, 40 confined cells 33 with non-ruptured nuclei and 60 confined cells with ruptured nuclei were scored per condition 34 35 per experiment. (C) RPE1 cells were confined at 2 µm in the presence of Propidium lodide and imaged overnight. Graph, data represents the mean ± SD of 3 independent experiments where 36 5 random fields (at 20x magnification) were scored per time point per experiment. Bar, 50µm. 37 38 (D) Epifluorescence and phase images of RPE1 cells stably expressing catalytically inactive 39 cGAS-EGFP (icGAS) harvested from 2 µm confinement and replated for cell cycle duration measurement over a 72 h period. Bar, 25 µm. Inset shows a cell with ruptured NE, as 40 evidenced by cGAS perinuclear accumulation. (E) Graph: box and whisker plot showing the 41 median value and 10-90 percentiles of the ratio between the SD of HP1y intensity and HP1y 42 43 mean intensity (coefficient of variation). This is an alternative way of quantifying the increase in the number of HP1y foci in the nucleus, without counting the foci. This globally measures 44 the coefficient of variation of the signal, which increases when the signal becomes less 45 homogeneous. Data represents 3 independent experiments where 70 cells were scored per 46 47 condition per experiment. (F) MCF10A cells or (G) DCIS cells were confined for 12 h at 10 or 2 µm, harvested from confinement and replated for 72 h before fixation for immunostaining 48 49 with heterochromatin foci (HP1y) or lysis for western blot analysis of lamin B1 and p21. GAPDH

is the loading control. Western blot images are representative of 2 independent experiments. 1 Graph, box and whisker plot showing the median value and 10-90 percentiles of the number 2 of HP1y foci per nucleus. Data represents 3 independent experiments where 100 cells per 3 condition per experiment were analyzed. Bars, 10 µm. (H) Western blot analysis of whole cell 4 extracts of human fibroblasts, RPE1 cells and HeLa cells. GAPDH is the loading control. (I) 5 cGAMP measurements for the indicated cells lines. Bars represent 1 experiment that was 6 performed in duplicate. P values were calculated by One-way ANOVA with post hoc Tukey 7 test (A) or unpaired Student's t-test (F, G). ***P < 0.0001; *P < 0.05; ns = not significant. 8

9

Figure S6. Pharmacologically induced DNA damage promotes collagen degradation 10 independently of TREX1 and cGAS and strong confinement induces cell polarization 11 and collagen degradation in a cGAS-independent fashion (related to Figure 5) TREX1 12 KO clones display normal proliferation both in vitro and in vivo (related to Figure 6). (A) 13 DCIS cells were treated for 12 h with the indicated concentrations of doxorubicin or DMSO 14 (vehicle). Following the incubation period, cells were harvested and embedded in 3D type I 15 collagen for 12 h to assess their collagen degradation activity by immunostaining with an 16 antibody that specifically recognizes the collagenase-cleaved ³/₄ fragment of collagen I. Graph, 17 box and whisker plot showing the median value and 10-90 percentiles of the collagen 18 degradation area. Data was normalized by the mean of control samples. Data represents 3 19 20 independent experiments where 50 cells per condition per experiment were analyzed. (B) Quantification of nuclear area of DCIS cells embedded into 3D collagen following the indicated 21 confinement heights. Graph, box and whisker plot showing the median value and 10-90 22 23 percentiles of nuclear projected area. Data represents 3 independent experiments where 70 cells per condition per experiment were analyzed. (C) DCIS cells stably expressing life actin-24 EGFP were confined for 2 h at the indicated heights. Following the confinement period, cells 25 were harvested and embedded in 3D type I collagen and imaged for 15 h. Bar, 20 µm. (D) 26 Scatter dot plots of different measured parameters while cells where embedded into 3D 27 collagen (lines are median). Data represents 2 independent experiments where 25 cells per 28 29 condition per experiment were analyzed. (E) DCIS cells were transiently depleted for TREX1 or cGAS using siRNA and 48 h later cells were pre-treated for 12 h with doxorubicin (Doxo, 80 30 31 nM) or DMSO (vehicle). Following the treatment period, cells were harvested and embedded in 3D type I collagen for 12 h to assess their collagen degradation activity by immunostaining 32 with an antibody that specifically recognizes the collagenase-cleaved 34 fragment of collagen 33 34 I. Graph, box and whisker plot showing the median value and 10-90 percentiles of the collagen degradation area. Data was normalized by the mean of control samples. Data represents 3 35 independent experiments where 40 cells per condition per experiment were analyzed. (F) 36 DCIS cells were transiently depleted for cGAS using siRNA and 48 h later cells were confined 37 at 2 µm for 2 h. Following the confinement period, cells were harvested and embedded in 3D 38 type I collagen for 12 h to assess their collagen degradation activity by immunostaining with 39 40 an antibody that specifically recognizes the collagenase-cleaved 3/4 fragment of collagen I (red); DAPI (cyan). Bar, 20 µm. Graph, box and whisker plot showing the median value and 41 10-90 percentiles of the collagen degradation area. Data was normalized by the mean of 42 control samples. Data represents 3 independent experiments where 60 cells per condition per 43 experiment were analyzed. Far right: western blot analysis of cGAS depletion (48 h post-44 45 knockdown); tubulin is a loading control. (G) Quantitative Real Time-PCR analysis. DCIS wt or TREX1 KO clones were confined at the indicated heights for 2 h. DCIS cells were harvested, 46 lysed and processed for analysis of the expression of mRNAs of EMT markers. (H) DCIS wt 47 cells were treated for the indicated lengths of time with DMSO (vehicle), Doxorubicin (80 nM) 48 or Etoposide (100 µM). Cells were harvested, lysed and processed for analysis of the 49 expression of mRNAs of EMT markers. Data represents the mean ± SD of 3 independent 50

experiments with 3 replicates per experiment. (I) DCIS wt cells were transiently depleted for 1 SNAIL1 and confined at the indicated heights for 2 h. Following the confinement period, cells 2 were harvested and embedded in 3D type I collagen for 12 h to assess their collagen 3 degradation activity by immunostaining with an antibody that specifically recognizes the 4 collagenase-cleaved ³/₄ fragment of collagen I. Graph, box and whisker plot showing the 5 median value and 10-90 percentiles of the collagen degradation area. Data was normalized by 6 the mean of control samples. Data represents 3 independent experiments where 60 cells per 7 8 condition per experiment were analyzed. Western blot shows SNAIL1 depletion 48 h postknockdown; tubulin is the loading control. (J) Graph showing the rate of in situ tumor burden 9 (period of 6-8 weeks post-intraductal injection). Data represents the mean ± SEM. A total of 4 10 11 parental and 11 TREX1 KO glands were analyzed. (K) Graph, box and whisker plot showing the median value and 10-90 percentiles of the tumor area generated by DCIS parental or 12 TREX1 KO clones (6-8 weeks post-intraductal injection). (L) Graph: box and whisker plot 13 14 showing the median value and 10-90 percentiles of the ratio between tumor area and gland area generated by DCIS parental or TREX1 KO clones (6-8 weeks post-intraductal injection). 15 Data represents a total of 7 glands scored for DCIS parental tumors and 14 glands for TREX1 16 KO tumors. (M) Proliferation curve of DCIS parental and clonesTREX1 KO#1 and TREX1 17 KO#2. Graph, data represents the mean ± SEM of 25 random fields scored at 20x 18 19 magnification. (N) Graphs showing the proportion of nuclei as a function of distance from the tumor edge (left) or Z score (yH2AX intensities) (right) for both TREX1 KO and TREX1 WT 20 mice xenografts. Data represents a total of 23 images analyzed for DCIS parental tumors and 21 22 30 images for TREX1 KO tumors (TREX1 KO #1 +TREX1 KO #2 clones) from 3 independent mice injections. P values were calculated by unpaired Student's t-test (B, D, F, I, J-L), One-23 way ANOVA with post hoc Tukey test (A, E). ***P < 0.0001; *P < 0.05; ns = not significant. See 24 25 also Movie S5.

26 Figure S7. Additional results commented in the discussion of the article, including analysis of TREX1 expression that reveals poor prognosis in breast cancer and cGAS 27 staining in human tumor samples (related to Figure 7). (A) cGAS antibody validation by 28 29 immunohistochemistry (IHC). (Top) DCIS were transiently transfected with siRNA control or siRNA cGAS and 72 hour later cells were paraffin embedded and formalyin fixed for IHC 30 31 processing. Bar, 40 µm. (Bottom) Quantitative RT-PCR showing cGAS mRNA levels (relative 32 to siControl-treated cells). (B) cGAS immunohistochemistry (brown) and nuclei (blue) in overtly invasive human breast ductal carcinoma. Insets 1 and 2: note cGAS accumulation at the tip of 33 ruptured nuclei. Red arrowheads point to NE rupture events. Left panels: bar, 25 µm and inset, 34 3 µm; middle panels: bar, 8 µm; right panels: bar, 3 µm. (C) RPE1 cells were transiently 35 36 transfected with RPA-GFP and either treated with hydroxyurea 2mM or confined at 3 µm and imaged for several minutes. Yellow arrowhead points to a nuclear bleb that eventually bursts. 37 Bar, 10 µm. (D) DCIS cells stably expressing Geminin-mCherry were treated with DMSO 38 (vehicle control) or doxorubicin (40 nM) and the percentage of cells in S/G2 was assessed at 39 0 h and 48 h of treatment; box and whisker plot shows the median value and 10-90 percentiles 40 of 2 independent experiments where at least 400 cells per experiment per condition were 41 analyzed. (E) DCIS cells stably expressing Geminin-mCherry were embedded in 3D type I 42 collagen for 12 h to assess their collagen degradation activity by immunostaining with an 43 antibody that specifically recognizes the collagenase-cleaved 3/4 fragment of collagen I; box 44 and whisker plot shows the median value and 10-90 percentiles of 2 independent experiments 45 where at least 100 cells per experiment were analyzed. (F) Kaplan Meier survival plot for 46 patients expressing low (black line) and high (red line) levels of TREX1 mRNA obtained by 47 RNAseq. Data was obtained from The Cancer Genome Atlas (TCGA), https://kmplot.com. (G) 48 MDA-MB-231 cells stably expressing 53BP1-EGFP and catalytically inactive cGAS-mCherry 49 (icGAS) were transiently depleted for TREX1 and confined at 2 µm. Bar, 10 µm. (H) 50

Quantification of DNA damage levels following 2 µm confinement as assessed by the number 1 of 53BP1 foci in MDA-MB-231 cells displaying or not NE rupture (siControl and siTREX1). Data 2 represents the mean of 2 independent experiments where 20 cells per experiment per 3 condition were analyzed. Western blot shows TREX1 depletion 48 h post-knockdown; tubulin 4 5 is the loading control. (I) Overview of immunohistochemistry analysis of moderately differentiated human colon rectal adenocarcinoma, infiltrating until muscle layer with perineural 6 invasion (classification: pT2). vH2AX (brown) and nuclei (blue). Bar, 1mm. (J) Magnified 7 regions of the invasive margin shown in "I". (Left) Immunohistochemistry of cGAS (brown) and 8 9 nuclei (blue). Yellow arrowheads point to NE rupture events. (Right) Immunohistochemistry of yH2AX (brown) and nuclei (blue). Bar, 20 µm. (K) Magnified regions of the healthy tissue from 10 the same patient. Bar, 20 µm. P values were calculated by unpaired Student's t-test, ***P < 11 0.0001; ns = not significant. 12

13

- 1
- 2

3 Supplementary Movies Legends

Movie S1. DCIS cells moving inside the duct on chip device (related to Figure 1). DCIS cells stably
 expressing 53BP1-mCherry were injected in the duct on chip and imaged using spinning disc
 microscopy (20x magnification).

Movie S2. RPE1 cells confined at 4 and 2 µm. (related to Figure 2). RPE1 cells stably expressing 53BP1-EGFP and catalytically inactive cGAS-mCherry were confined at 4 (first part of the movie) and 2 µm (second part of the movie) and imaged under 40x magnification using spinning disc microscopy. Cells confined at 4 µm exhibit no NE rupture and cGAS remains cytoplasmic while 53BP1 remains homogenous in the nucleus. At 2 µm sequential nuclear blebbing events are observed, leading to formation of cGAS cluster at the periphery of the nucleus, at the site of blebbing, and accumulation of 53BP1 in multiple foci in the nucleus.

Movie S3. Examples of non-confined RPE1 cells with spontaneous NE rupture and subsequent DNA damage (related to Figure 2). RPE1 cells stably expressing 53BP1-EGFP and catalytically inactive cGAS-mCherry were seeded on a glass bottom dish and imaged under 40x magnification using wide field fluorescence microscopy.

Movie S4. TREX1 nuclear localization upon confinement (related to Figure 3). RPE1 cells were transiently transfected with TREX1-EGFP and 1µm thickness Z slices were acquired before and after 2µm confinement. Cells were imaged under 40x magnification using spinning disc microscopy.

Movie S5. DCIS cells subjected to strong confinement exhibit exploratory behavior in 3D collagen (related to Figure 5). DCIS cells stably expressing life-actin-EGFP were confined at 10µm or 2µm for 2h. Subsequently, cells were harvested and embedded in a 3D collagen matrix for imaging under 40x magnification using spinning disc microscopy.

25

26 **References:**

- 27 Basit, A., Cho, M.G., Kim, E.Y., Kwon, D., Kang, S.J., and Lee, J.H. (2020). The
- cGAS/STING/TBK1/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels. Exp. Mol. Med.

Behbod, F., Kittrell, F.S., LaMarca, H., Edwards, D., Kerbawy, S., Heestand, J.C., Young, E.,
Mukhopadhyay, P., Yeh, H.W., Allred, D.C., et al. (2009). An intraductal human-in-mouse
transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res.

Benci, J.L., Johnson, L.R., Choa, R., Xu, Y., Qiu, J., Zhou, Z., Xu, B., Ye, D., Nathanson,
K.L., June, C.H., et al. (2019). Opposing Functions of Interferon Coordinate Adaptive and
Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell.

Le Berre, M., Aubertin, J., and Piel, M. (2012). Fine control of nuclear confinement identifies a threshold deformation leading to lamina rupture and induction of specific genes. Integr. Biol. *4*, 1406.

Le Berre, M., Zlotek-Zlotkiewicz, E., Bonazzi, D., Lautenschlaeger, F., and Piel, M. (2014). Methods for Two-Dimensional Cell Confinement. In Methods in Cell Biology, pp. 213–229.

Blaha, L., Zhang, C., Cabodi, M., and Wong, J.Y. (2017). A microfluidic platform for modeling
 metastatic cancer cell matrix invasion. Biofabrication.

- 43 Castagnino, A., Castro-Castro, A., Irondelle, M., Guichard, A., Lodillinsky, C., Fuhrmann, L.,
- 44 Vacher, S., Agüera-González, S., Zagryazhskaya-Masson, A., Romao, M., et al. (2018).
- 45 Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-
- 46 MMP traffic and invadopodia function. Oncogene.

- 1 Cho, S., Vashisth, M., Abbas, A., Majkut, S., Vogel, K., Xia, Y., Ivanovska, I.L., Irianto, J.,
- Tewari, M., Zhu, K., et al. (2019). Mechanosensing by the Lamina Protects against Nuclear
 Rupture, DNA Damage, and Cell-Cycle Arrest. Dev. Cell.
- 4 Chowdhury, D., Beresford, P.J., Zhu, P., Zhang, D., Sung, J.S., Demple, B., Perrino, F.W.,
- 5 and Lieberman, J. (2006). The Exonuclease TREX1 Is in the SET Complex and Acts in
- 6 Concert with NM23-H1 to Degrade DNA during Granzyme A-Mediated Cell Death. Mol. Cell.
- 7 Denais, C.M., Gilbert, R.M., Isermann, P., McGregor, A.L., te Lindert, M., Weigelin, B.,
- 8 Davidson, P.M., Friedl, P., Wolf, K., and Lammerding, J. (2016). Nuclear envelope rupture
- 9 and repair during cancer cell migration. Science (80-.). 352, 353–358.
- Earle, A.J., Kirby, T.J., Fedorchak, G.R., Isermann, P., Patel, J., Iruvanti, S., Moore, S.A.,
 Bonne, G., Wallrath, L.L., and Lammerding, J. (2020). Mutant lamins cause nuclear envelope
 rupture and DNA damage in skeletal muscle cells. Nat. Mater.
- 13 Erdal, E., Haider, S., Rehwinkel, J., Harris, A.L., and McHugh, P.J. (2017). A prosurvival
- DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1. Genes Dev.
- Feinberg, T.Y., Zheng, H., Liu, R., Wicha, M.S., Yu, S.M., and Weiss, S.J. (2018). Divergent
 Matrix-Remodeling Strategies Distinguish Developmental from Neoplastic Mammary
 Epithelial Cell Invasion Programs. Dev. Cell.
- Feng, C., Yang, M., Zhang, Y., Lan, M., Huang, B., Liu, H., and Zhou, Y. (2018). Cyclic
 mechanical tension reinforces DNA damage and activates the p53-p21-Rb pathway to
 induce premature senescence of nucleus pulposus cells. Int. J. Mol. Med.
- Friedl, P., and Gilmour, D. (2009). Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. Cell Biol.
- 24 Gentili, M., Lahaye, X., Nadalin, F., Nader, G.P.F., Lombardi, E.P., Herve, S., De Silva, N.S.,
- 25 Rookhuizen, D.C., Zueva, E., Goudot, C., et al. (2019). The N-Terminal Domain of cGAS
- 26 Determines Preferential Association with Centromeric DNA and Innate Immune Activation in
- 27 the Nucleus. Cell Rep.
- 28 Gorgoulis, V., Adams, P.D., Alimonti, A., Bennett, D.C., Bischof, O., Bishop, C., Campisi, J.,
- Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019). Cellular Senescence: Defining a Path
 Forward. Cell.
- Harding, S.M., Benci, J.L., Irianto, J., Discher, D.E., Minn, A.J., and Greenberg, R.A. (2017).
- Mitotic progression following DNA damage enables pattern recognition within micronuclei.Nature.
- Hatch, E.M. (2018). Nuclear envelope rupture: little holes, big openings. Curr. Opin. Cell Biol.
- Hatch, E.M., and Hetzer, M.W. (2016). Nuclear envelope rupture is induced by actin-based
 nucleus confinement. J. Cell Biol.
- Infante, E., Castagnino, A., Ferrari, R., Monteiro, P., Agüera-González, S., Paul-Gilloteaux,
 P., Domingues, M.J., Maiuri, P., Raab, M., Shanahan, C.M., et al. (2018). LINC complex-Lis1
- interplay controls MT1-MMP matrix digest-on-demand response for confined tumor cellmigration. Nat. Commun.
- Irianto, J., Xia, Y., Pfeifer, C.R., Athirasala, A., Ji, J., Alvey, C., Tewari, M., Bennett, R.R.,
- 42 Harding, S.M., Liu, A.J., et al. (2017). DNA Damage Follows Repair Factor Depletion and
- 43 Portends Genome Variation in Cancer Cells after Pore Migration. Curr. Biol.
- Jiang, Y.N., Ni, X.Y., Yan, H.Q., Shi, L., Lu, N.N., Wang, Y.N., Li, Q., and Gao, F.G. (2019). Interleukin 6-triggered ataxia-telangiectasia mutated kinase activation facilitates epithelial-to-

- 1 mesenchymal transition in lung cancer by upregulating vimentin expression. Exp. Cell Res.
- Kang, H.T., Park, J.T., Choi, K., Kim, Y., Choi, H.J.C., Jung, C.W., Lee, Y.S., and Park, S.C.
 (2017). Chemical screening identifies ATM as a target for alleviating senescence. Nat.
- 4 Chem. Biol.
- 5 Kim, M., Kim, H.J., Chung, Y.R., Kang, E., Kim, E.K., Kim, S.H., Kim, Y.J., Kim, J.H., Kim, 6 I.A., and Park, S.Y. (2018). Microinvasive carcinoma versus ductal carcinoma in situ: A
- comparison of clinicopathological features and clinical outcomes. J. Breast Cancer.
- 8 Lahaye, X., Satoh, T., Gentili, M., Cerboni, S., Conrad, C., Hurbain, I., El Marjou, A.,
- 9 Lacabaratz, C., Lelièvre, J.-D., and Manel, N. (2013). The Capsids of HIV-1 and HIV-2
- 10 Determine Immune Detection of the Viral cDNA by the Innate Sensor cGAS in Dendritic
- 11 Cells. Immunity *39*, 1132–1142.
- 12 Lee-Kirsch, M.A., Chowdhury, D., Harvey, S., Gong, M., Senenko, L., Engel, K., Pfeiffer, C.,
- Hollis, T., Gahr, M., Perrino, F.W., et al. (2007a). A mutation in TREX1 that impairs
- susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J. Mol.Med.
- Lee-Kirsch, M.A., Gong, M., Chowdhury, D., Senenko, L., Engel, K., Lee, Y.A., De Silva, U., Bailey, S.L., Witte, T., Vyse, T.J., et al. (2007b). Mutations in the gene encoding the 3'-5'
- Bailey, S.L., Witte, T., Vyse, T.J., et al. (2007b). Mutations in the gene encoding the 3'-5'
 DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet.
- 18 DNA exonuclease TREXT are associated with systemic tupus erythematosus. Nat. Genet.
- Lehtinen, D.A., Harvey, S., Mulcahy, M.J., Hollis, T., and Perrino, F.W. (2008). The TREX1
 double-stranded DNA degradation activity is defective in dominant mutations associated with
 autoimmune disease. J. Biol. Chem.
- Liu, H., Zhang, H., Wu, X., Ma, D., Wu, J., Wang, L., Jiang, Y., Fei, Y., Zhu, C., Tan, R., et al. (2018). Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. Nature.
- Liu, Y.-J., Le Berre, M., Lautenschlaeger, F., Maiuri, P., Callan-Jones, A., Heuzé, M., Takaki,
 T., Voituriez, R., and Piel, M. (2015). Confinement and Low Adhesion Induce Fast Amoeboid
 Migration of Slow Mesenchymal Cells. Cell *160*, 659–672.
- Lodillinsky, C., Infante, E., Guichard, A., Chaligné, R., Fuhrmann, L., Cyrta, J., Irondelle, M.,
 Lagoutte, E., Vacher, S., Bonsang-Kitzis, H., et al. (2016). p63/MT1-MMP axis is required for
 in situ to invasive transition in basal-like breast cancer. Oncogene.
- Lusk, C.P., and Ader, N.R. (2020). CHMPions of repair: Emerging perspectives on sensing and repairing the nuclear envelope barrier. Curr. Opin. Cell Biol. *64*, 25–33.
- Maciejowski, J., Li, Y., Bosco, N., Campbell, P.J., and De Lange, T. (2015). Chromothripsis and Kataegis Induced by Telomere Crisis. Cell.
- Maciejowski, J., Chatzipli, A., Dananberg, A., Lange, T. de, and Campbell, P. (2019).
- APOBEC3B-dependent kataegis and TREX1-driven chromothripsis in telomere crisis.
 BioRxiv.
- Malhas, A., Goulbourne, C., and Vaux, D.J. (2011). The nucleoplasmic reticulum: Form and function. Trends Cell Biol.
- Malinverno, C., Corallino, S., Giavazzi, F., Bergert, M., Li, Q., Leoni, M., Disanza, A., Frittoli,
- 40 E., Oldani, A., Martini, E., et al. (2017). Endocytic reawakening of motility in jammed 41 epithelia. Nat. Mater.
- 42 Martinvalet, D., Zhu, P., and Lieberman, J. (2005). Granzyme A induces caspase-
- 43 independent mitochondrial damage, a required first step for apoptosis. Immunity.
- 44 Mayhew, T.M. (2011). Mapping the distributions and quantifying the labelling intensities of
- 45 cell compartments by immunoelectron microscopy: Progress towards a coherent set of

- 1 methods. J. Anat. 219, 647–660.
- Mazur, D.J., and Perrino, F.W. (2001). Excision of 3' termini by the Trex1 and TREX2 3'→5'
 exonucleases. Characterization of the recombinant proteins. J. Biol. Chem.
- Mohr, L., Toufektchan, E., von Morgen, P., Chu, K., Kapoor, A., and Maciejowski, J. (2021).
 ER-directed TREX1 limits cGAS activation at micronuclei. Mol. Cell *81*, 724-738.e9.
- 6 Palamidessi, A., Malinverno, C., Frittoli, E., Corallino, S., Barbieri, E., Sigismund, S.,
- 7 Beznoussenko, G. V., Martini, E., Garre, M., Ferrara, I., et al. (2019). Unjamming overcomes
- kinetic and proliferation arrest in terminally differentiated cells and promotes collectivemotility of carcinoma. Nat. Mater.
- Peng, B., Ortega, J., Gu, L., Chang, Z., and Li, G.M. (2019). Phosphorylation of proliferating
 cell nuclear antigen promotes cancer progression by activating the ATM/Akt/GSK3β/Snail
 signaling pathway. J. Biol. Chem.
- Raab, M., Gentili, M., de Belly, H., Thiam, H.-R., Vargas, P., Jimenez, A.J., Lautenschlaeger,
 F., Voituriez, R., Lennon-Dumenil, A.-M., Manel, N., et al. (2016). ESCRT III repairs nuclear
 envelope ruptures during cell migration to limit DNA damage and cell death. Science (80-.).
- 16 352, 359–362.
- Robijns, J., Houthaeve, G., Braeckmans, K., and De Vos, W.H. (2018). Loss of Nuclear
 Envelope Integrity in Aging and Disease. In International Review of Cell and Molecular
- 19 Biology, p.
- 20 Roman, W., Martins, J.P., Carvalho, F.A., Voituriez, R., Abella, J.V.G., Santos, N.C., Cadot,
- B., Way, M., and Gomes, E.R. (2017). Myofibril contraction and crosslinking drive nuclear
 movement to the periphery of skeletal muscle. Nat. Cell Biol.
- Shah, P., Wolf, K., and Lammerding, J. (2017). Bursting the Bubble Nuclear Envelope
 Rupture as a Path to Genomic Instability? Trends Cell Biol.
- Shah, P., Hobson, C.M., Cheng, S., Colville, M.J., Paszek, M.J., Superfine, R., and
- Lammerding, J. (2021). Nuclear Deformation Causes DNA Damage by Increasing Replication Stress. Curr. Biol. *31*, 753-765.e6.
- Slot, J.W., and Geuze, H.J. (2007). Cryosectioning and immunolabeling. Nat. Protoc. 2,
 2480–2491.
- Srivastava, N., de Freitas Nader, G.P., Williart, A., Rollin, R., Cuvelier, D., Lomakin, A., and Piel, M. (2021). Nuclear fragility, blaming the blebs. Curr. Opin. Cell Biol. *70*, 100–108.
- Stetson, D.B., Ko, J.S., Heidmann, T., and Medzhitov, R. (2008). Trex1 Prevents Cell Intrinsic Initiation of Autoimmunity. Cell.
- Sun, M., Guo, X., Qian, X., Wang, H., Yang, C., Brinkman, K.L., Serrano-Gonzalez, M., Jope,
 R.S., Zhou, B., Engler, D.A., et al. (2012). Activation of the ATM-Snail pathway promotes
 breast cancer metastasis. J. Mol. Cell Biol. *4*, 304–315.
- Takahashi, A., Loo, T.M., Okada, R., Kamachi, F., Watanabe, Y., Wakita, M., Watanabe, S.,
- Kawamoto, S., Miyata, K., Barber, G.N., et al. (2018). Downregulation of cytoplasmic
- DNases is implicated in cytoplasmic DNA accumulation and SASP in senescent cells. Nat.
 Commun.
- Teuliere, J. (2005). Targeted activation of -catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development *132*, 267–277.
- Ungricht, R., and Kutay, U. (2015). Establishment of NE asymmetry-targeting of membrane proteins to the inner nuclear membrane. Curr. Opin. Cell Biol. *34*, 135–141.

- 1 Vanpouille-Box, C., Alard, A., Aryankalayil, M.J., Sarfraz, Y., Diamond, J.M., Schneider, R.J.,
- 2 Inghirami, G., Coleman, C.N., Formenti, S.C., and Demaria, S. (2017). DNA exonuclease
- 3 Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun.
- Vargas, J.D., Hatch, E.M., Anderson, D.J., and Hetzer, M.W. (2012). Transient nuclear
 envelope rupturing during interphase in human cancer cells. Nucleus.
- 6 De vos, W.H., Houben, F., Kamps, M., Malhas, A., Verheyen, F., Cox, J., Manders, E.M.M.,
- 7 Verstraeten, V.L.R.M., Van steensel, M.A.M., Marcelis, C.L.M., et al. (2011). Repetitive
- 8 disruptions of the nuclear envelope invoke temporary loss of cellular compartmentalization in
- 9 laminopathies. Hum. Mol. Genet.
- 10 Yang, Y.G., Lindahl, T., and Barnes, D.E. (2007). Trex1 Exonuclease Degrades ssDNA to
- 11 Prevent Chronic Checkpoint Activation and Autoimmune Disease. Cell.
- 12

CellPress

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		-
RAB5A	Abcam	Cat# ab109534
γΗ2ΑΧ	Abcam	Cat# ab11174
Rabbit monoclonal anti-Ku70 (clone EPR4026)	Abcam	Cat# ab108604; RRID:
		AB_10861861
Rabbit monoclonal anti-p21 (clone ERF3993)	Abcam	Cat# ab109199; RRID:
		AB_10861551
Mouse monoclonal anti-Ki67 (clone MIB-1)	Agilent	Cat# M7240; RRID:
		AB_2142367
Mouse monoclonal anti-alpha SMA (clone 1A4)	Agilent	Cat# M0851; RRID:
		AB_2223500
Rabbit polyclonal anti-RIF1	Bethyl Laboratories	Cat# A300-569A
Rabbit monoclonal anti-cGAS (clone D1D3G)	Cell Signaling	Cat# 15102; RRID:
	Technology	AB_2732795
Rabbit monoclonal anti-TREX1 (clone D8E2O) (discontinued)	Cell Signaling	Cat# 15107; RRID:
	Technology	AB_2798710
Rabbit monoclonal anti-GAPDH (clone 14C10)	Cell Signaling	Cat# 2118, RRID:
	Technology	AB_561053
Rabbit monoclonal anti-Snail1 (clone C15D3)	Cell Signaling	Cat# 3879, RRID:
	Technology	AB_2255011
Mouse monoclonal anti-PDI (clone 1D3)	Enzo LifeSciences	Cat# ADI-SPA-891,
Dah bit na halana lanti na Channa	Constant	RKID: AB_10615355
Rabbit polycional anti-mCherry	Genetex	Cat# G1X128508;
Pabhit polyclopal anti Col1 2/4C (collagonaso cloaved 2/4		Cot# #0217 050
fragment of collagen I)		Cal# #0217-030
Mouse monoclonal anti-phospho-Histone H2A X (Ser139)	Millinore	Cat# 05-636: BBID:
(clone IBW301)	wimpore	AB 309864
Mouse monoclonal anti-HP1v (clone 14D3.1)	Millipore	Cat# MABE656: RRID:
		AB 2722628
Mouse monoclonal anti-TREX1 (clone E-6)	Santa Cruz	Cat# sc-271870; RRID:
	Biotechnology	AB 10708266
Mouse monoclonal anti-laminB1 (clone A-11)	Santa Cruz	Cat# sc-377000, RRID:
	Biotechonology	AB_2861346
Mouse monoclonal anti-αtubulin (clone DM1A)	Sigma-Aldrich	Cat# T9026; RRID:
		AB_477593
Biological samples		
Human Breast Ductal Adenocarcinoma tissue sections	Archival anonymized	claudio.tripodo@unip
	tumor tissue collection;	a.it
	Tumor Immunology	
	Unit, Department of	
	Health Sciences,	
	University of Palermo	
	School of Medicine	
Chemicals, peptides, and recombinant proteins		
KU-55933 (ATM kinase inhibitor)	Abcam	Cat# 120637; CAS:
		587871-26-9
Unlabeled type I collagen	BD Biosciences	Cat# 354236

CellPress

Technology33419-2.0DoxorubicinCell Signaling Technology23316-0.9Penicillin StreptomycinGibcoCat# 51201Unlabeled type I collagen, Smg/mlIBI0Cat# 5201GMS001 (matrix metalloproteinases pan-inhibitor)MilliporeCat# Cat# 7100-15; CAS: 62253-63-8HydrocortisoneSigma-AldrichCat# 021023.7Cholera toxinSigma-AldrichCat# 0228; CAS: 9012-63-9InsulinSigma-AldrichCat# 0228; CAS: 11061-68-011061-68-0HT-DNADeoxyribonucleic acid sodium saltSigma-AldrichCat# 0228; CAS: 012-63-9InsulinSigma-AldrichCat# 12270Protein A gold conjugatesUtrecht University, The N/AN/AHarris's HematoxylinBio-OpticaCat# 05-06004/LPL-g-PEGSuSoSCat# 051700Z'3'-CGAMP EUSA kitInterchimCat# 051700DAS Chromogen KitBio-OpticaCat# 051700Opal 7-Color IHC KitAkoya 23 BiosciencesCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, 10314Originally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 KS tably expressing icGAS-mcherry and 33891-GFPN/AHuman, female: RPE1 KK to Stably expressing icGAS- Chavirer, institut Curie, ParisOriginally ATCC CRL- 10317Human, female: RPE1 REX IK KO stably expressing icGAS- Chavirer, institut Curie, ParisOriginally ATCC CRL- 10317Human, female: RPE1 REX IK KO stably	Etoposide	Cell Signaling	Cat# 2200; CAS:				
DoxonubicinCell Signaling TechnologyCatt 527; CAS: 2316-40-9Pencillin StreptomycinGibcoCatt 15140-122Unlabeled type I collagen, 5mg/mlIBIDCatt 5201GM6001 (matrix metalloproteinases pan-inhibitor)MilliporeCatt CC1010Human EGFPeprotechCatt ACD-15; CAS: 62253-6-3HydrocortisoneSigma-AldrichCatt H0888; CAS: 50- 23-7Cholera toxinSigma-AldrichCatt 8052; CAS: 9012-63-9InsulinSigma-AldrichCatt 8052; CAS: 9012-63-9InsulinSigma-AldrichCatt 8052; CAS: 438545-06-3HT-DNA Deoxyribonucleic acid sodium salt from herring testesSigma-AldrichCatt 8052; CAS: 438545-06-3Harrig's HematoxylinBio-OpticaCatt 6005; CAS: 438545-06-3Harris's HematoxylinBio-OpticaCatt 90-06004/LpLL-g-PEGSuSoSCatt 90-06004/LpLL-g-PEGSuSoSCatt 90-06004/LZ'3'-CGAMP ELISA kitInterchimCatt 90-06004/LDAB Chromogen KitBioCare MedicalCatt 90801LVulcan fast red Chromogen KitBioCare MedicalCatt 90-06004/LUnama, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: RPE1 tably expressing icGAS-mcherry and 538P1-GFPN/AN/AHuman, female: MCF10A stably expressing icGAS-mcherry and 538P1-GFPN/AN/AHuman, female: MCF10A stably expressing icGAS-mcherry and 538P1-GFPOriginally ATCC CRL- 10317Originally ATCC CRL- 10317 <td></td> <td>Technology</td> <td>33419-42-0</td>		Technology	33419-42-0				
Technology25316-40-9Unlabeled type I collagen, Smg/mlGibcoCat# 15140-122Unlabeled type I collagen, Smg/mlIBIDICat# 50201GM5001 (matrix metalloproteinases pan-inhibitor)MilliporeCat# 45100-15; CAS: 62253-38HydrocortisoneSigma-AldrichCat# 4F-100-15; CAS: 62253-38HydrocortisoneSigma-AldrichCat# 46805; CAS: 9012-63-9InsulinSigma-AldrichCat# 1988; CAS: 50- 23-7Cholera toxinSigma-AldrichCat# 1978; CAS: 11061-88-0HT-DNA Deoxyribonucleic acid sodium salt from herring testesSigma-AldrichCat# 19278; CAS: 43854-06-3MatrigelSigma-AldrichCat# 1520Protein A gold conjugatesUtrecht University, The NYAN/AHarris's HematoxylinBio-OpticaCat# 05-06004/LpLL-g-PEGSuSoSCat# 1100Critical commercial assaysZat# 50-63Z'3-CGAMP ELISA kitInterchimCat# 501700DAS Chromogen KitBioCare MedicalCat# R805MOpal7-Color IHC KitAkoya 23 BiosciencesCat# 11081/AVulcan fast red Chromogen KitBioCare MedicalCat# R805MOpal7-Color IHC KitAkoya 23 BiosciencesCat# 14000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 Stably expressing icGAS-mcherry and S38P1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, femal	Doxorubicin	Cell Signaling	Cat# 5927; CAS:				
Pencifilin StreptomycinGibcoCat# 15140-122Unlabeled type I collagen, Smg/mlIBIDICat# 50201GM6001 (matrix metalloproteinases pan-inhibitor)MilliporeCat# C1010Human EGFPeprotechCat# Ac100-15; CA5: 62253-G3-8HydrocortisoneSigma-AldrichCat# B088; CA5: 50- 23-7Cholera toxinSigma-AldrichCat# B088; CA5: 50- 23-7InsulinSigma-AldrichCat# B088; CA5: 51- 23-7InsulinSigma-AldrichCat# B089; CA5: 11061-68-0HT-DNA Deoxyribonucleic acid sodium salt from herring testesSigma-AldrichCat# B1270HT-DNA Deoxyribonucleic acid sodium saltSigma-AldrichCat# E1270Protein A gold conjugatesUtrecht University, The N/AN/AHarris's HematoxylinBio-OpticaCat# 050-6004/LpLL-g-PEGSuSoSCat# 50700Z'3'-GAMP ELISA kitInterchimCat# 501700DAB Chromogen KitBioCare MedicalCat# D100DAB Chromogen KitBioCare MedicalCat# B0801LVulcan fast red Chromogen KitBioCare MedicalCat# B0801LUuran, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: MCF10ACatS-GS-mcherry and 538P1-GFPOriginally ATCC CRL- Davier, Institut Curie, ParisHuman, female: MCF10A stably expressing icGAS-mcherry and 538P1-GFP		Technology	25316-40-9				
Unlabeled type I collagen, 5mg/mlIBIDCat# 2C1010GM6001 (matrix metalloproteinases pan-inhibitor)MilliporeCat# 2C1010Human EGFPeprotechCat# 4F:100-15; CAS: 6223-36-38HydrocortisoneSigma-AldrichCat# H088; CAS: 50- 23-7Cholera toxinSigma-AldrichCat# H088; CAS: 50- 23-7InsulinSigma-AldrichCat# 1027; CAS: 11061-68:00HT-DNA Deoxyribonucleic acid sodium saltSigma-AldrichCat# 1027; CAS: 11061-68:00MatrigelSigma-AldrichCat# 10270Protein A gold conjugatesUtrecht University, The N/AN/AHarris's HematoxylinBio-OpticaCat# 050004/LPL-g-PEGSuSoSCat# 10270Z'3'-CGAMP ELISA kitInterchimCat# 501700DAB Chromogen KitBioCare MedicalCat# R805MOpal7-Color IHC KitAkoya 23 BiosciencesCat# R805MUuran fast red Chromogen KitBioCare MedicalCat# FR805MOpal7-Color IHC KitLab of Dr. Matthieu Piel, 4000Originally ATCC CRL- 4000Human, female: RPE1Lab of Dr. Matthieu Piel, 4000Originally ATCC CRL- 4000Human, female: MCF10ALab stably expressing icGAS-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10ALab of Dr. Philippe Chavrier, institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 538P1-GFP	Penicillin Streptomycin	Gibco	Cat# 15140-122				
GM6001 (matrix metalloproteinases pan-inhibitor)MilliporeCat# AF-100-15; CAS; 6223-63-8HydrocortisoneSigma-AldrichCat# AF-100-15; CAS; 6223-63-8HydrocortisoneSigma-AldrichCat# AF-100-15; CAS; 6223-63-8InsulinSigma-AldrichCat# (1923; CAS; 9012-63-9InsulinSigma-AldrichCat# (19278; CAS; 1106-16-8-0HT-DNA Deoxyribonucleic acid sodium salt from herring testesSigma-AldrichCat# (19278; CAS; 1106-18-8-0MatrigelSigma-AldrichCat# E1270Protein A gold conjugatesUtrecht University, The N/AN/AHarris's HematoxylinBio-OpticaCat# 600-0004/LPL-g-PEGSuSoSCat# 501700DAB Chromogen KitBioCare MedicalCat# 501700DAB Chromogen KitBioCare MedicalCat# 700Vulcan fast red Chromogen KitBioCare MedicalCat# FB805MOpal 7-Color IHC KitAkoya 23 BiosciencesCat# RE21001KTHuman, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: RPE1 TREX1 KOThis paperN/AHuman, female: MCF10ALab of SaP1-GFPN/AHuman, female: MCF10ALab of SaP1-GFPOriginally ATCC CRL- 10317Human, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 538P1	Unlabeled type I collagen, 5mg/ml	IBIDI	Cat# 50201				
Human EGFPeprotechCat# AF-100-15; CAS: 62253-63-8HydrocortisoneSigma-AldrichCat# H0888; CAS: 50-2 23-7Cholera toxinSigma-AldrichCat# (C052; CAS: 9012-63-9InsulinSigma-AldrichCat# (C052; CAS: 9012-63-9InsulinSigma-AldrichCat# (C052; CAS: 9012-63-9HT-DNA Deoxyribonucleic acid sodium salt from herring testesSigma-AldrichCat# (C052; CAS: 9012-63-9MatrigelSigma-AldrichCat# (D528; CAS: 438545-06-3MatrigelProtein A gold conjugatesUtrecht University, The N/AN/AHarris's HematoxylinBio-OpticaCat# 05-06004/LCritical commercial assaysCat# 05-06004/LCat# 05-06004/L2'3'-cGAMP ELISA kitInterchimCat# 05-06004/LQala Chromogen KitBioCare MedicalCat# 050700DAB Chromogen KitBioCare MedicalCat# 050700Uvalcan fast red Chromogen KitBioCare MedicalCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, Institut Curie, ParisOrginally ATCC CRL- 4000Human, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOrginally ATCC CRL- 4000Human, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavier, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: MCF10ALab of Dr. Philippe Chavier, Institut Curie, ParisOriginally ATCC CRL- 4000Human, fe	GM6001 (matrix metalloproteinases pan-inhibitor)	Millipore	Cat# CC1010				
Hydrocortisone6223-63-8HydrocortisoneSigma-AldrichCat# H0888; CAS: 50-23-7Cholera toxinSigma-AldrichCat# C8052; CAS: 9012-63-9InsulinSigma-AldrichCat# C8052; CAS: 1061-68-0HT-DNADeoxyribonucleic acid sodium salt from herring testesSigma-AldrichAttractSigma-AldrichCat# D6898; CAS: 438545-06-3MatrigelSigma-AldrichCat# D6898; CAS: 438545-06-3Protein A gold conjugatesUtrecht University, The NetherlandsN/AHarris's HematoxylinBio-OpticaCat# D5-06004/LpLL-g-PEGSuSoSCat# PLL(20)-g[3.5]- PEG(2)Critical commercial assays2'2'-cGAMP ELISA kitInterchimZ'3'-cGAMP ELISA kitInterchimCat# 501700DAB Chromogen KitBioCare MedicalCat# FR805MOpal 7-Color IHC KitAkoya 23 BiosciencesCat# NEL821001KTExperimental models: Cell linesHuman, female: RPE1 Institut Curie, ParisOriginally ATCC CRL- Institut Curie, ParisHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavirer, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 538P1-GFPLab of Dr. Philippe Chavirer, Institut Curie, Paris : Behbod et al. 2009Originally ATCC CRL- 10317Human, female: MCF10DCIS.comLab of Dr. Philippe Chavirer, Institut Curie, Paris : Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)	Human EGF	Peprotech	Cat# AF-100-15; CAS:				
HydrocortisoneSigma-AldrichCat# H0888; CAS: 50-23-7Cholera toxinSigma-AldrichCat# (8052; CAS: 9012-63-9InsulinSigma-AldrichCat# (28052; CAS: 11061-68-0HT-DNADeoxyribonucleic acid sodium saltSigma-AldrichCat# 19278; CAS: 43854-06-3MatrigelSigma-AldrichCat# D6898, CAS: 43854-06-3MatrigelSigma-AldrichCat# 1270Protein A gold conjugatesUtrecht University, The N/AHarris's HematoxylinBio-OpticaCat# 05-06004/LPL-g-PEGSuSoSCat# 05-06004/L2'3'-GGAMP ELISA kitInterchimCat# 501700DAB Chromogen KitBioCare MedicalCat# F0700DAB Chromogen KitBioCare MedicalCat# FR805MVulcan fast red Chromogen KitBioCare MedicalCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL-4000Human, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL-4000Human, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS-mcherry and 538P1-GFPN/AHuman, female: MCF10ALab of Dr. Philippe Chavier, Institut Curie, ParisOriginally ATCC CRL-10317Human, female: MCF10A stably expressing icGAS-mcherry and 538P1-GFPLab of Dr. Philippe Chavier, Institut Curie, ParisOriginally ATCC CRL-10317Human, female: MCF10DCIS.comLab of Dr. Philippe Chavier, Institut Curie, ParisOriginally ATCC CRL-10317Human, female: MCF10DCIS.com<			62253-63-8				
Cholera toxinSigma-AldrichCat# C8052; CAS: 9012-63-9InsulinSigma-AldrichCat# 105278; CAS: 11061-68-0HT-DNA Deoxyribonucleic acid sodium salt from herring testesSigma-AldrichCat# 105278; CAS: 11061-68-0MatrigelSigma-AldrichCat# E1270Protein A gold conjugatesUtrecht University, The NLAN/AHarris's HematoxylinBio-OpticaCat# 05-06004/LPLL-g-PEGSuSoSCat# 91(20)-g[3.5]- PEG(2)Critical commercial assays2'3'-cGAMP ELISA kitInterchimCat# 501700DAB Chromogen KitBioCare MedicalCat# VB801LVulcan fast red Chromogen KitBioCare MedicalCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 TREX1 KOThis paperN/AHuman, female: RCF10ALab of Dr. Philippe Chavirer, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: RCF10ALab of Dr. Philippe Chavirer, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: RCF10DCIS.comLab of Dr. Philippe Chavirer, Institut Curie, ParisOriginally from Asterand (Detroit, MI, USA)	Hydrocortisone	Sigma-Aldrich	Cat# H0888; CAS: 50- 23-7				
InsulinSigma-AldrichCat# I9278; CAS: 11061-68-0HT-DNADeoxyribonucleic acid sodium saltSigma-AldrichCat# D6298; CAS: 438545-06-3from herring testesSigma-AldrichCat# E1270Protein A gold conjugatesUtrecht University, The NetherlandsN/AHarris's HematoxylinBio-OpticaCat# 05-06004/LpLL-g-PEGSuSoSCat# 05-06004/LCritical commercial assaysInterchimCat# 5017002'3'-cGAMP ELISA kitInterchimCat# 501700DAB Chromogen KitBioCare MedicalCat# D8801LVulcan fast red Chromogen KitBioCare MedicalCat# NEL821001KTExperimental models: Cell linesExperimental models: Cell linesOriginally ATCC CRL- 	Cholera toxin	Sigma-Aldrich	Cat# C8052; CAS: 9012-63-9				
International control of the second	Insulin	Sigma-Aldrich	Cat# 19278; CAS:				
HT-DNADeoxyribonucleic acid sodium salt from herring testesSigma-AldrichCat# D889 ; CAS: 438545-06-3MatrigelSigma-AldrichCat# E1270Protein A gold conjugatesUtrecht University, The NetherlandsN/AHarris's HematoxylinBio-OpticaCat# 05-06004/LpLL-g-PEGSuSoSCat# 05-06004/LCritical commercial assaysE2'3'-cGAMP ELISA kitInterchimCat# 501700DAB Chromogen KitBioCare MedicalCat# D8801LVulcan fast red Chromogen KitBioCare MedicalCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, 			11061-68-0				
from herring testes43854-06-3MatrigelSigma-AldrichCat# E1270Protein A gold conjugatesUtrecht University, The NetherlandsN/AHarris's HematoxylinBio-OpticaCat# 05-06004/LpLL-g-PEGSuSoSCat# PLL(20)-g[3.5]- PEG(2)Critical commercial assays2'3'-cGAMP ELISA kitInterchimCat# 501700DA Ehromogen KitBioCare MedicalCat# FR805MVulcan fast red Chromogen KitBioCare MedicalCat# R805MOpal7-Color IHC KitAkoya 23 BiosciencesCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-mcherry and 33BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: RCF10ALab of Dr. Philippe Chavrier, Institut Curie, Paris'Originally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPN/AOriginally ATCC CRL- 10317Human, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, Paris' Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)	HT-DNA Deoxyribonucleic acid sodium salt	Sigma-Aldrich	Cat# D6898 ; CAS:				
MatrigelSigma-AldrichCat# E1270Protein A gold conjugatesUtrecht University, The NetherlandsN/AHarris's HematoxylinBio-OpticaCat# 92-06004/LpLL-g-PEGSuSoSCat# PLL(20)-g[3.5]- PEG(2)Critical commercial assays	from herring testes		438545-06-3				
Protein A gold conjugatesUtrecht University, The NetherlandsN/AHarris's HematoxylinBio-OpticaCat# 05-06004/LpLL-g-PEGSuSoSCat# PLL(20)-g[3.5]- PEG(2)Critical commercial assaysInterchimCat# 501700Z'3'-cGAMP ELISA kitInterchimCat# 501700DAB Chromogen KitBioCare MedicalCat# DB801LVulcan fast red Chromogen KitBioCare MedicalCat# FR805MOpal7-Color IHC KitAkoya 23 BiosciencesCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPN/AOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPN/AOriginally ATCC CRL- 10317Human, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)	Matrigel	Sigma-Aldrich	Cat# E1270				
Harris's HematoxylinBio-OpticaCat# 05-06004/LpLL-g-PEGSuSoSCat# PLL(20)-g[3.5]- PEG(2)Critical commercial assays	Protein A gold conjugates	Utrecht University, The Netherlands	N/A				
pLL-g-PEGSuSoSCat# PLL(20)-g[3.5]- PEG(2)Critical commercial assays	Harris's Hematoxylin	Bio-Optica	Cat# 05-06004/L				
Def g 1EGSubbrCell (12) g (3.5) PEG(2)Critical commercial assays2'3'-cGAMP ELISA kitInterchimCat# 501700DAB Chromogen KitBioCare MedicalCat# DB801LVulcan fast red Chromogen KitBioCare MedicalCat# FR805MOpal7-Color IHC KitAkoya 23 BiosciencesCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)		SuSoS	Cat# PLL(20)-g[3 5]-				
Critical commercial assays2'3'-cGAMP ELISA kitInterchimCat# 501700DAB Chromogen KitBioCare MedicalCat# DB801LVulcan fast red Chromogen KitBioCare MedicalCat# FR805MOpal7-Color IHC KitAkoya 23 BiosciencesCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPCriginally ATCC CRL- 10317Human, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)		SUSOS Cat# PLL(20)-g[3.5]- PEG(2)					
2'3'-cGAMP ELISA kit Interchim Cat# 501700 DAB Chromogen Kit BioCare Medical Cat# DB801L Vulcan fast red Chromogen Kit BioCare Medical Cat# FR805M Opal 7-Color IHC Kit Akoya 23 Biosciences Cat# NEL821001KT Experimental models: Cell lines Lab of Dr. Matthieu Piel, Institut Curie, Paris Originally ATCC CRL- 4000 Human, female: RPE1 Lab of Dr. Matthieu Piel, Institut Curie, Paris Originally ATCC CRL- 4000 Human, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFP This paper N/A Human, female: RPE1 TREX1 KO This paper N/A Human, female: RPE1 TREX1 KO This paper N/A Human, female: RPE1 TREX1 KO Lab of Dr. Philippe Chavrier, Institut Curie, Paris Originally ATCC CRL- 10317 Human, female: MCF10A Lab of Dr. Philippe Chavrier, Institut Curie, Paris Originally ATCC CRL- 10317 Human, female: MCF10DCIS.com Lab of Dr. Philippe Chavrier, Institut Curie, Paris Originally from Asterand (Detroit, MI, USA)	Critical commercial assays						
DAB Chromogen KitBioCare MedicalCat# DB801LVulcan fast red Chromogen KitBioCare MedicalCat# FR805MOpal 7-Color IHC KitAkoya 23 BiosciencesCat# NEL821001KTExperimental models: Cell linesCat# NEL821001KTHuman, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)							
Vulcan fast red Chromogen KitBioCare MedicalCat# FR805MOpal 7-Color IHC KitAkoya 23 BiosciencesCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 stably expressing icGAS-mcherry and 33BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry 	2'3'-cGAMP ELISA kit	Interchim	Cat# 501700				
Vulcan fast red Chromogen KitBioCare MedicalCat# FR805MOpal 7-Color IHC KitAkoya 23 BiosciencesCat# NEL821001KTExperimental models: Cell linesLab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally from Asterand (Detroit, MI, USA)	2'3'-cGAMP ELISA kit DAB Chromogen Kit	Interchim BioCare Medical	Cat# 501700 Cat# DB801L				
OpalColor IHC KitAkoya 23 BiosciencesCat# NEL821001KTExperimental models: Cell linesOriginally ATCC CRL- 4000Human, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPLab of Dr. Philippe 	2'3'-cGAMP ELISA kit DAB Chromogen Kit	Interchim BioCare Medical	Cat# 501700 Cat# DB801L				
Opal7-Color IHC KitAkoya 23 BiosciencesCat# NEL821001K1Experimental models: Cell linesHuman, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPLab of Dr. Philippe Chavrier, Institut Curie, 	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit	Interchim BioCare Medical BioCare Medical	Cat# 501700 Cat# DB801L Cat# FR805M				
Experimental models: Cell linesHuman, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: RCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit	Interchim BioCare Medical BioCare Medical	Cat# 501700 Cat# DB801L Cat# FR805M				
Human, female: RPE1Lab of Dr. Matthieu Piel, Institut Curie, ParisOriginally ATCC CRL- 4000Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPLab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally from Asterand (Detroit, MI, USA)	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit	Interchim BioCare Medical BioCare Medical Akoya 23 Biosciences	Cat# 501700 Cat# DB801L Cat# FR805M Cat# NEL821001KT				
Human, female: RPE1 stably expressing icGAS-GFPThis paperN/AHuman, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines	Interchim BioCare Medical BioCare Medical Akoya 23 Biosciences	Cat# 501700 Cat# DB801L Cat# FR805M Cat# NEL821001KT				
Human, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPN/AHuman, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1	Interchim BioCare Medical BioCare Medical Akoya 23 Biosciences Lab of Dr. Matthieu Piel, Institut Curie, Paris	Cat# 501700 Cat# DB801L Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000				
S3BP1-GFPN/AHuman, female: RPE1 TREX1 KOThis paperN/AHuman, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1 Human, female: RPE1 stably expressing icGAS-GFP	Interchim BioCare Medical BioCare Medical Akoya 23 Biosciences Lab of Dr. Matthieu Piel, Institut Curie, Paris This paper	Cat# 501700 Cat# DB801L Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000 N/A				
Human, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFP This paper N/A Human, female: MCF10A Lab of Dr. Philippe Chavrier, Institut Curie, Paris Originally ATCC CRL- 10317 Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFP This paper N/A Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFP This paper N/A Human, female: MCF10DCIS.com Lab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al. 2009 Originally from Asterand (Detroit, MI, USA)	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1 Human, female: RPE1 stably expressing icGAS-GFP Human, female: RPE1 stably expressing icGAS-mcherry and	Interchim BioCare Medical BioCare Medical Akoya 23 Biosciences Lab of Dr. Matthieu Piel, Institut Curie, Paris This paper This paper	Cat# 501700 Cat# DB801L Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000 N/A N/A				
Human, Temale: RPE1 TREXT KO stably expressing icGAS- This paper N/A mcherry and 53BP1-GFP Lab of Dr. Philippe Originally ATCC CRL- Human, female: MCF10A Lab of Dr. Philippe 10317 Human, female: MCF10A stably expressing icGAS-mcherry This paper N/A Human, female: MCF10A stably expressing icGAS-mcherry This paper N/A Human, female: MCF10DCIS.com Lab of Dr. Philippe Originally from Human, female: MCF10DCIS.com Lab of Dr. Philippe Originally from Asterand (Detroit, MI, Paris ; Behbod et al. USA) 2009 2009 Human Human	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1 Human, female: RPE1 stably expressing icGAS-GFP Human, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFP	Interchim BioCare Medical BioCare Medical Akoya 23 Biosciences Lab of Dr. Matthieu Piel, Institut Curie, Paris This paper This paper	Cat# 501700 Cat# DB801L Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000 N/A N/A				
Human, female: MCF10ALab of Dr. Philippe Chavrier, Institut Curie, ParisOriginally ATCC CRL- 10317Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFPThis paperN/AHuman, female: MCF10DCIS.comLab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al. 2009Originally from Asterand (Detroit, MI, USA)	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1 Human, female: RPE1 stably expressing icGAS-GFP Human, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFP Human, female: RPE1 TREX1 KO	Interchim BioCare Medical BioCare Medical Akoya 23 Biosciences Lab of Dr. Matthieu Piel, Institut Curie, Paris This paper This paper	Cat# 501700 Cat# DB801L Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000 N/A N/A N/A				
Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFP This paper N/A Human, female: MCF10DCIS.com Lab of Dr. Philippe Originally from Chavrier, Institut Curie, Asterand (Detroit, MI, Paris ; Behbod et al. USA) 2009	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1 Human, female: RPE1 stably expressing icGAS-GFP Human, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFP Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFP	InterchimBioCare MedicalBioCare MedicalBioCare MedicalAkoya 23 BiosciencesLab of Dr. Matthieu Piel, Institut Curie, ParisThis paperThis paperThis paperThis paperThis paperThis paperThis paper	Cat# 501700 Cat# DB801L Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000 N/A N/A N/A N/A N/A				
Human, female: MCF10DCIS.comLab of Dr. PhilippeOriginally fromChavrier, Institut Curie, Paris ; Behbod et al.Asterand (Detroit, MI, USA)2009	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1 Human, female: RPE1 stably expressing icGAS-GFP Human, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFP Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO stably expressing icGAS- mcherry and 53BP1-GFP Human, female: MCF10A	InterchimBioCare MedicalBioCare MedicalBioCare MedicalAkoya 23 BiosciencesLab of Dr. Matthieu Piel, Institut Curie, ParisThis paperThis paperThis paperThis paperThis paperLab of Dr. Philippe Chavrier, Institut Curie, Paris	Cat# 501700 Cat# DB801L Cat# FR805M Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000 N/A N/A N/A N/A Originally ATCC CRL- 10317				
Chavrier, Institut Curie, Asterand (Detroit, MI, Paris ; Behbod et al. USA) 2009	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1 Human, female: RPE1 stably expressing icGAS-GFP Human, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFP Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO Human, female: MCF10A Human, female: MCF10A	InterchimBioCare MedicalBioCare MedicalBioCare MedicalAkoya 23 BiosciencesLab of Dr. Matthieu Piel, Institut Curie, ParisThis paperThis paperThis paperThis paperThis paperLab of Dr. Philippe Chavrier, Institut Curie, ParisThis paper	Cat# 501700 Cat# DB801L Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000 N/A N/A N/A N/A Originally ATCC CRL- 10317 N/A				
Paris ; Behbod et al. USA) 2009	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1 Human, female: RPE1 stably expressing icGAS-GFP Human, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFP Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO Human, female: MCF10A Human, female: MCF10A	InterchimBioCare MedicalBioCare MedicalBioCare MedicalAkoya 23 BiosciencesLab of Dr. Matthieu Piel, Institut Curie, ParisThis paperThis paperThis paperThis paperThis paperLab of Dr. Philippe Chavrier, Institut Curie, ParisThis paperLab of Dr. PhilippeLab of Dr. PhilippeLab of Dr. PhilippeLab of Dr. Philippe	Cat# 501700 Cat# DB801L Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000 N/A N/A N/A N/A Originally ATCC CRL- 10317 N/A Originally from				
2009	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1 Human, female: RPE1 stably expressing icGAS-GFP Human, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFP Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO Human, female: MCF10A Stably expressing icGAS-mcherry and 53BP1-GFP Human, female: MCF10A stably expressing icGAS-mcherry and 53BP1-GFP Human, female: MCF10DCIS.com	InterchimBioCare MedicalBioCare MedicalBioCare MedicalAkoya 23 BiosciencesLab of Dr. Matthieu Piel, Institut Curie, ParisThis paperThis paperThis paperThis paperThis paperLab of Dr. Philippe Chavrier, Institut Curie, ParisThis paperLab of Dr. Philippe Chavrier, Institut Curie, ParisLab of Dr. Philippe Chavrier, Institut Curie, Paris	Cat# 501700 Cat# DB801L Cat# FR805M Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000 N/A N/A N/A N/A Originally ATCC CRL- 10317 N/A Originally from Asterand (Detroit, MI.				
	2'3'-cGAMP ELISA kit DAB Chromogen Kit Vulcan fast red Chromogen Kit Opal 7-Color IHC Kit Experimental models: Cell lines Human, female: RPE1 Human, female: RPE1 stably expressing icGAS-GFP Human, female: RPE1 stably expressing icGAS-mcherry and 53BP1-GFP Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO Human, female: RPE1 TREX1 KO Human, female: MCF10A Human, female: MCF10A	InterchimBioCare MedicalBioCare MedicalBioCare MedicalAkoya 23 BiosciencesLab of Dr. Matthieu Piel, Institut Curie, ParisThis paperThis paperThis paperThis paperThis paperLab of Dr. Philippe Chavrier, Institut Curie, ParisThis paperLab of Dr. Philippe Chavrier, Institut Curie, ParisLab of Dr. Philippe Chavrier, Institut Curie, Paris ; Behbod et al.	Cat# 501700 Cat# DB801L Cat# FR805M Cat# FR805M Cat# NEL821001KT Originally ATCC CRL- 4000 N/A N/A N/A N/A Originally ATCC CRL- 10317 N/A Originally from Asterand (Detroit, MI, USA)				



Human, female: MCF10DCIS.com stably expressing icGAS- mcherry and 53BP1-GFP	This paper	N/A	
Human, female: MCF10DCIS.com TREX1 KO	This paper	N/A	
Human, female: MCF10DCIS.com TREX1 KO stably expressing	This paper	N/A	
Human, female: MDA-MB-231	Lab of Dr. Philippe Chavrier, Institut Curie, Paris	Originally ATCC CRM- HTB-26	
Human, female: MDA-MB-231 stably expressing icGAS- mcherry and 53BP1-GFP	This paper	N/A	
Experimental models: Organisms/strains			
Mouse: CB17/Icr-Prkdc ^{scid} /IcrIcoCrI	Charles River	Strain code #236	
	Laboratories		
Oligonucleotides			
ON-TARGETplus SMARTpool siTREX1	Dharmacon	Cat# L-013239-02- 0005	
ON-TARGETplus SMARTpool sicGAS (MB21D1)	Dharmacon	Cat# L-015607-02- 0005	
ON-TARGETplus SMARTpool siSNAI1	Dharmacon	Cat# L-010847-01- 0005	
TREX1 guide RNA to generate CRISPR KO clones: 5'-GAGCCCCCCACCTCTC-(PAM)-3'	Maciejowski et al., 2015	Lab of Titia De Lange, Rockefeller University, New York, USA	
GAPDH: NM_001289746.1 (sequence copyright protected)	This paper	Thermo Fischer	
CDH2: NM_001308176.1 (sequence copyright protected)	This paper	Thermo Fischer	
VIM: NM_003380.3 (sequence copyright protected)	This paper	Thermo Fischer	
SNAI1: NM_005985.3 (sequence copyright protected)	This paper	Thermo Fischer	
SNAI2: NM_003068.4 (sequence copyright protected)	This paper	Thermo Fischer	
TWIST1: NM_000474.3 (sequence copyright protected)	This paper	Thermo Fischer	
ZEB1: NM_001128128.2 (sequence copyright protected)	This paper	Thermo Fischer	
Recombinant DNA			
pTRIP-CMV-mCherry-TREX1 WT	Lab of Dr. Nicolas Manel, Institut Curie, Paris	N/A	
pTRIP-CMV-mCherry-TREX1 D18N	Lab of Dr. Nicolas Manel, Institut Curie, Paris	N/A	
pLENTI-CMV-GFP-TREX1	Mohr et al., 2021	Addgene #164228	
pTRIP-SFFV-EGFP-FLAG-cGAS E225A/D227A	Raab et al., 2016; Gentili et al., 2019	Addgene #127661	
pTRIP-CMV-mCherry-FLAG-cGAS E225A/D227A	Gentili et al., 2019	Addgene #127657	
pTRIP-SFFV-EGFP-53BP1	Lab of Dr. Nicolas Manel, Institut Curie, Paris	N/A	
pLENTI-CMV-GFP-TREX1 deltaC (aa1-235)	Mohr et al., 2021	Addgene #164229	
pLENTI-CMV-GFP-TREX1 deltaC-sec61TM	Lab of Dr. John Maciejowski, MSKCC, NY	N/A	
pQCXIP-GFP-RPA70	Mohr et al., 2021	Addgene #164231	
Software and algorithms	,	·	



GraphPad Prism version 5.02	GraphPad	<u>https://www.graphpa</u> <u>d.com/</u>
Fiji ImageJ 1.52p	ImageJ	https://fiji.sc/
Image J macros	This paper	Mendeley Data doi: 10.17632/hbhv5brnxj. 1
Metamorph version 7.7.11.0	Molecular Devices, LLC	https://www.molecula rdevices.com/



Seeding density: IOW high

low high



0

NE rupture:

Figure 3



Figure 4









F





Figure 5

Figure 5







D



Figure 7

Α



В

С

Mouse xenograft



Mouse xenograft



Supplemental Figure 1

Figure Silick here to access/download;Supplemental Figure;Fig S1.pdf ±









Click here to access/download;Supplemental FigureFigureS5new 2021.08.09.pdf



Click here to access/download;Supplemental Figure Soure;FigureSonew 2021.08.09.pdf





Table S1 (relative to figure 3D). Testing for differences in the observed distributions of TREX1-mCherry labelled by gold particles between two groups of cells (not confined and 2µm confined), estimating observed and expected numbers of gold particles in a given compartment. For a particular compartment in a given cell, the number of expected gold particles was calculated by multiplying the corresponding column sum by the corresponding row sum and then dividing by the grand row sum. The compartment "Cytoplasm" also includes the gold particles associated to membranes such as ER and multivesicular bodies. Chi-square values accounting for 10% or more of total chi-square are considered to be significant. Refer to methods for a detailed explanation of this analysis (approach 1).

	Not co	nfined	Confined			X² (Chi-	square)	X² as %	
Compartment	observed	expected	observed	expected	row total	Not confined	Confined	Not confined	Confined
Nucleus	30	62.8	106 73.2		136	17.1361454	14.7042832	37.3566136	32.05518
Outer nuclear membrane	18	20.8	27	24.2	45	0.37229676	0.31946257	0.81160295	0.69642498
Cytoplasm	212	176.4	170	205.6	382	7.17921468	6.16038223	15.6506111	13.4295673
total	260		303		563	45.8717849		100	

Table S2 (relative to figures 3D and S4C). Testing for differences in specific-labelling enrichment of TREX1-mCherry gold particles between compartments in non-confined and 2µm confined RPE1 cells. The relative labelling index is estimated from observed and expected numbers of gold particles. LD=labelling density; RLD=Relative labelling index; Ngo= observed Nano gold particles; Nge=expected nano gold particles; Residuum= all the other cellular compartments. The expected distribution was obtained by superimposing to pictures an array of points that was generated digitally, and points (P) were counted in the selected compartments. For each compartment, Ngo was compared with the expected numbers of gold particles (Nge, derived from the observed frequencies of points P). Chi-square values accounting for 10% or more of total chi-square are considered to be significant and thus to contribute to the enrichment in the indicated compartments. Refer to methods for a detailed explanation of this analysis (approach 2).

Non confined									Confined					
Compartment	Ngo	Р	Nge	LD (=Ngo/P)	RLI (=LD/LD cell)	X² (Chi- square)	X² as %	Ngo	Ρ	Nge	LD (=Ngo/P)	RLI (=LD/LD cell)	X² (Chi- square)	X² as %
Nucleus	26	932	116.56	0.03	0.22	70.36	18.8	86	1560	176.11	0.06	0.49	46.11	16.3
Inner nuclear membrane	4	45	5.63	0.09	0.71	0.47	0.1	20	54	6.1	0.37	3.28	31.71	11.2
Outer nuclear membrane	18	19	2.38	0.95	7.58	102.73	27.5	27	44	4.97	0.61	5.44	97.73	34.5
Peripheral ER	29	45	5.63	0.64	5.15	97.07	26	20	27	3.05	0.74	6.56	94.28	33.2
Residuum	155	995	124.43	0.16	1.25	7.51	2	150	1719	194.06	0.09	0.77	10	3.5
Column sum	260	2079	260	0.13	1	373.3	100	303	2684	303	0.11	1	283.67	100